{
    "items": "146",
    "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
    "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
    "feed": [
        {
            "title": "Want $200 Per Month in Passive Income? Invest $80,000 in This Vanguard ETF",
            "url": "https://www.fool.com/investing/2024/04/07/want-200-per-month-in-passive-income-invest-80000/",
            "time_published": "20240407T081500",
            "authors": [
                "Demitri Kalogeropoulos"
            ],
            "summary": "Truly passive income is easy to find on the stock market.",
            "banner_image": "https://g.foolcdn.com/editorial/images/771536/businessman-working-on-laptop-with-diagram-graph-on-computer.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.189723,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "HD",
                    "relevance_score": "0.073546",
                    "ticker_sentiment_score": "0.184822",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.073546",
                    "ticker_sentiment_score": "0.184822",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.146469",
                    "ticker_sentiment_score": "0.235822",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.073546",
                    "ticker_sentiment_score": "0.184822",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Can a New CEO Fix Boeing?",
            "url": "https://www.fool.com/investing/2024/04/06/can-a-new-ceo-fix-boeing/",
            "time_published": "20240406T121500",
            "authors": [
                "Motley Fool Staff"
            ],
            "summary": "We also talk with e.l.f. Beauty CEO Tarang Amin about how the company is succeeding.",
            "banner_image": "https://g.foolcdn.com/editorial/images/771264/mfm_29.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999941"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.714479"
                }
            ],
            "overall_sentiment_score": 0.187821,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.011107",
                    "ticker_sentiment_score": "0.062517",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.055492",
                    "ticker_sentiment_score": "0.073",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.027763",
                    "ticker_sentiment_score": "0.016757",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BK",
                    "relevance_score": "0.005554",
                    "ticker_sentiment_score": "-0.054697",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DNUT",
                    "relevance_score": "0.083155",
                    "ticker_sentiment_score": "0.059964",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MASI",
                    "relevance_score": "0.044407",
                    "ticker_sentiment_score": "0.102612",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MA",
                    "relevance_score": "0.038861",
                    "ticker_sentiment_score": "0.010756",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.005554",
                    "ticker_sentiment_score": "0.220055",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.01666",
                    "ticker_sentiment_score": "-0.033408",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RBLX",
                    "relevance_score": "0.011107",
                    "ticker_sentiment_score": "0.207778",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HD",
                    "relevance_score": "0.083155",
                    "ticker_sentiment_score": "0.05988",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LRLCF",
                    "relevance_score": "0.005554",
                    "ticker_sentiment_score": "0.076157",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.033313",
                    "ticker_sentiment_score": "0.021151",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.01666",
                    "ticker_sentiment_score": "0.104468",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.066567",
                    "ticker_sentiment_score": "0.024171",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wall Street indexes rise after strong jobs data",
            "url": "https://www.moneycontrol.com/news/business/markets/wall-street-indexes-rise-after-strong-jobs-data-12586721.html",
            "time_published": "20240406T041428",
            "authors": [],
            "summary": "The Dow Jones Industrial Average rose 307.06 points, or 0.80%, to 38,904.04, the SP 500 gained 57.13 points, or 1.11%, to 5,204.34 and the Nasdaq Composite gained 199.44 points, or 1.24%, to 16,248.52.",
            "banner_image": "https://images.moneycontrol.com/static-mcnews/2020/08/wall-street-1.jpg?impolicy=website&width=168&height=118",
            "source": "Money Control",
            "category_within_source": "Markets",
            "source_domain": "www.moneycontrol.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.106364,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DNUT",
                    "relevance_score": "0.09439",
                    "ticker_sentiment_score": "0.062564",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.09439",
                    "ticker_sentiment_score": "0.175443",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.09439",
                    "ticker_sentiment_score": "0.28044",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.09439",
                    "ticker_sentiment_score": "0.28044",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ADTH, NVEI, SWAV",
            "url": "https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-adth-nvei-swav-302109621.html",
            "time_published": "20240406T013800",
            "authors": [
                "Halper Sadeh LLP"
            ],
            "summary": "NEW YORK, April 5, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: sale to Cadent, LLC for $3.21 per share.",
            "banner_image": "https://mma.prnewswire.com/media/1896150/Firm_Logo_with_Investor_Law_Firm_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.160445,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVEI",
                    "relevance_score": "0.166169",
                    "ticker_sentiment_score": "0.109574",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ADTH",
                    "relevance_score": "0.166169",
                    "ticker_sentiment_score": "0.117726",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.166169",
                    "ticker_sentiment_score": "0.11365",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Acquisition Watch: Time to Buy Johnson & Johnson  ( JNJ )  or ShockWave Medical's  ( SWAV )  Stock?",
            "url": "https://www.zacks.com/commentary/2251416/acquisition-watch-time-to-buy-johnson-johnson-jnj-or-shockwave-medicals-swav-stock",
            "time_published": "20240405T192700",
            "authors": [
                "Shaun Pruitt"
            ],
            "summary": "News of healthcare behemoth Johnson & Johnson (JNJ) acquiring medical device company ShockWave Medical (SWAV) for $13.1 billion made headlines this morning.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/f7/64441.jpg?v=1798740764",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.714479"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.287875,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.426824",
                    "ticker_sentiment_score": "0.364211",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Stocks Buck Strong Jobs Data; Nvidia Tests This Key Level As Tesla Falls On Stock Market Today",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-tesla-stock-nvidia-stock/",
            "time_published": "20240405T180100",
            "authors": [
                "VIDYA RAMAKRISHNAN",
                "Investor's Business Daily"
            ],
            "summary": "Stocks Buck Strong Jobs Data. Nvidia Tests This Key Level As Tesla Falls Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/02/Stock-Tesla-2024-model3-03-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999981"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.130705,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.127119",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARES",
                    "relevance_score": "0.127119",
                    "ticker_sentiment_score": "0.060216",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CELH",
                    "relevance_score": "0.127119",
                    "ticker_sentiment_score": "0.32558",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "0.068215",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.251032",
                    "ticker_sentiment_score": "0.021006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.127119",
                    "ticker_sentiment_score": "0.118523",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.127119",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDNDF",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "-0.12511",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VZ",
                    "relevance_score": "0.127119",
                    "ticker_sentiment_score": "-0.145434",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.127119",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AHHLF",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "0.279698",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.127119",
                    "ticker_sentiment_score": "-0.145434",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.18967",
                    "ticker_sentiment_score": "-0.111487",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.127119",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INTC",
                    "relevance_score": "0.127119",
                    "ticker_sentiment_score": "-0.145434",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.127119",
                    "ticker_sentiment_score": "-0.145434",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NOW",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "0.052019",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRT",
                    "relevance_score": "0.127119",
                    "ticker_sentiment_score": "0.32558",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.127119",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MMYT",
                    "relevance_score": "0.127119",
                    "ticker_sentiment_score": "0.32558",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, KTRA, ABIO - ARCA biopharma  ( NASDAQ:ABIO ) , Kintara Therapeutics  ( NASDAQ:KTRA ) ",
            "url": "https://www.benzinga.com/pressreleases/24/04/g38115003/shareholder-investigation-halper-sadeh-llc-investigates-swav-ktra-abio",
            "time_published": "20240405T174428",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "NEW YORK, April 05, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Shockwave Medical, Inc.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.114747,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ABIO",
                    "relevance_score": "0.118647",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KTRA",
                    "relevance_score": "0.118647",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.118647",
                    "ticker_sentiment_score": "0.087791",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.118647",
                    "ticker_sentiment_score": "0.087791",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "CURE Media Group and Oncology Nursing News announce Kristen Dahlgren as keynote speaker for the 2024 Extraordinary Healer® event",
            "url": "https://www.benzinga.com/pressreleases/24/04/g38113091/cure-media-group-and-oncology-nursing-news-announce-kristen-dahlgren-as-keynote-speaker-for-the-20",
            "time_published": "20240405T160000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "CRANBURY, N.J., April 05, 2024 ( GLOBE NEWSWIRE ) -- CURE® Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to more than 1 million patients, survivors and caregivers, partners with Oncology Nursing News®, a multimedia platform dedicated to ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.402117,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.047465",
                    "ticker_sentiment_score": "0.314033",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Uptrend Under Pressure; Tesla, Humana In Focus: Weekly Review",
            "url": "https://www.investors.com/news/market-rally-under-pressure-tesla-humana-in-focus/",
            "time_published": "20240405T154500",
            "authors": [
                "Investor's Business Daily",
                "IBD STAFF"
            ],
            "summary": "Uptrend Under Pressure. Tesla, Humana In Focus: Weekly Review Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/08/WallStreetFinance2-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.918141"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.858979"
                }
            ],
            "overall_sentiment_score": -0.056248,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "XPEV",
                    "relevance_score": "0.074345",
                    "ticker_sentiment_score": "-0.040646",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVS",
                    "relevance_score": "0.074345",
                    "ticker_sentiment_score": "-0.012255",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HUM",
                    "relevance_score": "0.148045",
                    "ticker_sentiment_score": "0.032097",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ULTA",
                    "relevance_score": "0.074345",
                    "ticker_sentiment_score": "-0.024013",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.111315",
                    "ticker_sentiment_score": "-0.125097",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.037213",
                    "ticker_sentiment_score": "0.038998",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RIVN",
                    "relevance_score": "0.074345",
                    "ticker_sentiment_score": "0.057445",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.037213",
                    "ticker_sentiment_score": "0.010975",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.148045",
                    "ticker_sentiment_score": "0.032097",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.291038",
                    "ticker_sentiment_score": "-0.049159",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NIO",
                    "relevance_score": "0.074345",
                    "ticker_sentiment_score": "-0.040646",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INTC",
                    "relevance_score": "0.111315",
                    "ticker_sentiment_score": "-0.15039",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "SBH",
                    "relevance_score": "0.074345",
                    "ticker_sentiment_score": "-0.024013",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TM",
                    "relevance_score": "0.074345",
                    "ticker_sentiment_score": "-0.113655",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UPS",
                    "relevance_score": "0.074345",
                    "ticker_sentiment_score": "0.124162",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FDX",
                    "relevance_score": "0.074345",
                    "ticker_sentiment_score": "0.124162",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LI",
                    "relevance_score": "0.074345",
                    "ticker_sentiment_score": "-0.040646",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.111315",
                    "ticker_sentiment_score": "0.044984",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stock Market Heads Higher After Robust Jobs Data; Tech Rally Led By Amazon, AMD, Netflix",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-nasdaq-sp500-nflx-stock-amazon-stock-amd-stock/",
            "time_published": "20240405T144900",
            "authors": [
                "KEN SHREVE",
                "Investor's Business Daily"
            ],
            "summary": "Stock Market Heads Higher After Robust Jobs Data. Tech Rally Led By Amazon, AMD, Netflix Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/02/Stock-MarketBoard-Blue42-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.121495,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.123844",
                    "ticker_sentiment_score": "0.458347",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.123844",
                    "ticker_sentiment_score": "-0.018486",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.184834",
                    "ticker_sentiment_score": "0.054592",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.118094",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.123844",
                    "ticker_sentiment_score": "-0.018486",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FTAI",
                    "relevance_score": "0.123844",
                    "ticker_sentiment_score": "0.458347",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.123844",
                    "ticker_sentiment_score": "0.060651",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.184834",
                    "ticker_sentiment_score": "0.054592",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRT",
                    "relevance_score": "0.123844",
                    "ticker_sentiment_score": "0.458347",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.123844",
                    "ticker_sentiment_score": "0.364372",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.184834",
                    "ticker_sentiment_score": "0.020215",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.123844",
                    "ticker_sentiment_score": "0.060651",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stock market today: Wall Street gains ground following surprisingly strong US jobs report",
            "url": "https://apnews.com/article/stock-markets-inflation-cdeea722367b960f1a87b0b3d287fedd",
            "time_published": "20240405T142300",
            "authors": [
                "DAMIAN J. TROISE"
            ],
            "summary": "Stock market today: Wall Street edges higher following surprisingly strong US jobs report The Associated Press ...",
            "banner_image": "https://dims.apnews.com/dims4/default/21218c3/2147483647/strip/true/crop/4604x3067+279+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fac%2Fa8%2Fea39c40eac6d2050674802e2afce%2Fe22a3195291746b885c2907906788a90",
            "source": "Associated Press",
            "category_within_source": "Markets",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.9545"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.104508,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.072",
                    "ticker_sentiment_score": "0.046611",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.072",
                    "ticker_sentiment_score": "0.152117",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Johnson & Johnson Buys Shockwave For $13.1 Billion In Latest Cardio Deal",
            "url": "https://www.forbes.com/sites/tylerroush/2024/04/05/johnson--johnson-buys-shockwave-for-131-billion-in-latest-cardio-deal/",
            "time_published": "20240405T140145",
            "authors": [
                "Ty Roush"
            ],
            "summary": "Johnson & Johnson will acquire Shockwave Medical in a deal valued at $13.1 billion, according to a joint statement Friday, the latest acquisition by the pharmaceutical firm over the last two years as it expands on cardiovascular intervention.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/661003dc039b388009779395/0x0.jpg?format=jpg&crop=4126,2320,x0,y231,safe&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.151974,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.113062",
                    "ticker_sentiment_score": "0.127301",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.522854",
                    "ticker_sentiment_score": "0.298251",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "J&J to pump another $13B into its MedTech business with Shockwave deal",
            "url": "https://apnews.com/article/johnsonshockwavemedtechdeal-fb308f70ee276b007fa759007913ee77",
            "time_published": "20240405T125600",
            "authors": [
                "TOM MURPHY"
            ],
            "summary": "Johnson & Johnson is pumping more money into heart care with a roughly $13 billion deal for Shockwave Medical, which specializes in technology that helps open clogged arteries. The health care giant said Friday that it will spend $335 in cash for each share of Shockwave.",
            "banner_image": "https://dims.apnews.com/dims4/default/d4a7cdd/2147483647/strip/true/crop/8640x5755+0+2/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2Fbf%2Ff6%2Fabd1b09cae88948a1ef55d90b377%2Fb489ad7e1b74464e8247e371365d6597",
            "source": "Associated Press",
            "category_within_source": "Business",
            "source_domain": "apnews.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.234915,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.21686",
                    "ticker_sentiment_score": "0.29379",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.109455",
                    "ticker_sentiment_score": "0.282005",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Johnson & Johnson Makes Yet Another Multi-Billion MedTech Deal With Shockwave Medical - Johnson & Johnson  ( NYSE:JNJ ) , Shockwave Medical  ( NASDAQ:SWAV ) ",
            "url": "https://www.benzinga.com/news/large-cap/24/04/38108776/johnson-johnson-makes-yet-another-multi-billion-medtech-deal-with-shockwave-medical",
            "time_published": "20240405T123520",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Friday, Johnson & Johnson JNJ agreed to acquire Shockwave Medical Inc SWAV for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion, including cash acquired.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Johnson-Johnson-logo-in-front-of-one-of-_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.162565,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SSTK",
                    "relevance_score": "0.09186",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.355588",
                    "ticker_sentiment_score": "0.382019",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.700945",
                    "ticker_sentiment_score": "0.338851",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Futures Bounce Ahead Of Jobs Report",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-jobs-report-meta-stock-nvidia-nvda-tesla-tsla/",
            "time_published": "20240405T120500",
            "authors": [
                "Investor's Business Daily",
                "SCOTT LEHTONEN"
            ],
            "summary": "Stock Market Today: Dow Jones Bounces Ahead Of Jobs Report. Meta, Nvidia, Tesla Rally Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.121747,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.119235",
                    "ticker_sentiment_score": "0.052268",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.079656",
                    "ticker_sentiment_score": "-0.06924",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.079656",
                    "ticker_sentiment_score": "0.012417",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.197413",
                    "ticker_sentiment_score": "0.167288",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ANET",
                    "relevance_score": "0.079656",
                    "ticker_sentiment_score": "0.013546",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.158519",
                    "ticker_sentiment_score": "0.039063",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VZ",
                    "relevance_score": "0.158519",
                    "ticker_sentiment_score": "0.013825",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.079656",
                    "ticker_sentiment_score": "0.165989",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NOW",
                    "relevance_score": "0.119235",
                    "ticker_sentiment_score": "0.010524",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HUBS",
                    "relevance_score": "0.079656",
                    "ticker_sentiment_score": "-0.031868",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.039878",
                    "ticker_sentiment_score": "0.113657",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.079656",
                    "ticker_sentiment_score": "0.165989",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Johnson & Johnson to Buy Shockwave Medical. It's a Cardio Health Play.",
            "url": "https://www.barrons.com/amp/articles/johnson-johnson-jnj-stock-shockwave-medical-de83a930",
            "time_published": "20240405T111200",
            "authors": [
                "Adam Clark"
            ],
            "summary": "Johnson & Johnson agreed to acquire medical-devices maker Shockwave Medical for a total enterprise value of about $13.1 billion. Johnson & Johnson will pay $335 a share in cash for Shockwave , J&J said in a statement Friday.",
            "banner_image": "https://images.barrons.com/im-459065/social",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.159966,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.145145",
                    "ticker_sentiment_score": "0.316577",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.727604",
                    "ticker_sentiment_score": "0.214185",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Johnson & Johnson to buy equipment maker Shockwave Medical for $12.5 bn",
            "url": "https://www.business-standard.com/companies/news/johnson-johnson-to-buy-equipment-maker-shockwave-medical-for-12-5-bn-124040500649_1.html",
            "time_published": "20240405T110649",
            "authors": [
                "Reuters"
            ],
            "summary": "Johnson & Johnson on Friday agreed to buy Shockwave Medical for $12.5 billion, in a deal that would help broaden its portfolio of medical devices used in treating heart diseases.",
            "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-12/05/full/1701794396-0294.jpg?im=FeatureCrop,size=(826,465)",
            "source": "Business Standard",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.business-standard.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.333493,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.327366",
                    "ticker_sentiment_score": "0.568925",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.327366",
                    "ticker_sentiment_score": "0.568925",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Johnson & Johnson To Buy Shockwave Medical For $13.1 Billion",
            "url": "https://www.investors.com/news/technology/johnson-johnson-to-buy-shockwave-medical-13-1-billion/",
            "time_published": "20240405T105500",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "Dow Jones giant Johnson & Johnson ( JNJ ) said it would acquire Shockwave Medical ( SWAV ) for $13.1 billion, or $335 a share. Both stocks rose slightly early Friday. SWAV stock had surged 68% to 319.99 as of April 4 in 2024, with takeover speculation among the driving forces.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2022/10/NEWAM_shockwave_101422_BizWire.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.116556,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.866386",
                    "ticker_sentiment_score": "-0.303934",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.739411",
                    "ticker_sentiment_score": "-0.023317",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Contineum Therapeutics Announces Pricing of Initial Public Offering",
            "url": "https://www.globenewswire.com/news-release/2024/04/05/2858269/0/en/Contineum-Therapeutics-Announces-Pricing-of-Initial-Public-Offering.html",
            "time_published": "20240405T010200",
            "authors": [
                "Contineum Therapeutics",
                "Inc."
            ],
            "summary": "SAN DIEGO, April 04, 2024 ( GLOBE NEWSWIRE ) -- Contineum Therapeutics, Inc. ( Contineum ) , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the ...",
            "banner_image": "",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.967645"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.112845,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.107016",
                    "ticker_sentiment_score": "0.062762",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.107016",
                    "ticker_sentiment_score": "0.062762",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.053629",
                    "ticker_sentiment_score": "0.057",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Contineum Therapeutics Announces Pricing of Initial Public Offering",
            "url": "https://www.benzinga.com/pressreleases/24/04/g38103690/contineum-therapeutics-announces-pricing-of-initial-public-offering",
            "time_published": "20240405T010200",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "SAN DIEGO, April 04, 2024 ( GLOBE NEWSWIRE ) -- Contineum Therapeutics, Inc. ( Contineum ) , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.98396"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.124562,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.102013",
                    "ticker_sentiment_score": "0.059706",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.102013",
                    "ticker_sentiment_score": "0.059706",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.051111",
                    "ticker_sentiment_score": "0.054974",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth",
            "url": "https://www.benzinga.com/pressreleases/24/04/g38089871/over-52-million-myeloma-warriors-reached-creating-ripples-across-the-globe-for-myelomaactionmonth",
            "time_published": "20240404T124500",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "STUDIO CITY, Calif., April 04, 2024 ( GLOBE NEWSWIRE ) -- At the conclusion of this year's Myeloma Action Month, the International Myeloma Foundation ( IMF ) was truly grateful and overwhelmed by everyone's support in making the annual campaign a global success -with over 52 million reached in ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.357125,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.060439",
                    "ticker_sentiment_score": "0.097145",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.020163",
                    "ticker_sentiment_score": "0.178796",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KPTI",
                    "relevance_score": "0.020163",
                    "ticker_sentiment_score": "0.178796",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MHRE",
                    "relevance_score": "0.020163",
                    "ticker_sentiment_score": "0.135277",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSVT",
                    "relevance_score": "0.020163",
                    "ticker_sentiment_score": "0.178796",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSC",
                    "relevance_score": "0.020163",
                    "ticker_sentiment_score": "0.236926",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.020163",
                    "ticker_sentiment_score": "0.178796",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.020163",
                    "ticker_sentiment_score": "0.178796",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.020163",
                    "ticker_sentiment_score": "0.178796",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates",
            "url": "https://www.globenewswire.com/news-release/2024/04/04/2857682/8624/en/Trinity-Biotech-Announces-Fourth-Quarter-and-Fiscal-Year-2023-Financial-Results-Business-Updates.html",
            "time_published": "20240404T113000",
            "authors": [
                "Trinity Biotech plc"
            ],
            "summary": "DUBLIN, Ireland, April 04, 2024 ( GLOBE NEWSWIRE ) -- Trinity Biotech plc ( Nasdaq: TRIB ) , a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/23a9d0e4-6c22-4509-971e-0c09c45ec985",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.130286,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "TRIB",
                    "relevance_score": "0.093087",
                    "ticker_sentiment_score": "0.059695",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.010366",
                    "ticker_sentiment_score": "0.059081",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:EUR",
                    "relevance_score": "0.010366",
                    "ticker_sentiment_score": "0.118508",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board - NextCure  ( NASDAQ:NXTC ) ",
            "url": "https://www.benzinga.com/pressreleases/24/04/g38087012/nextcure-appoints-dr-rakesh-dixit-to-scientific-advisory-board",
            "time_published": "20240404T110500",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "BELTSVILLE, Md., April 04, 2024 ( GLOBE NEWSWIRE ) -- NextCure, Inc. NXTC, a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.326251,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.195025",
                    "ticker_sentiment_score": "0.298482",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NXTC",
                    "relevance_score": "0.541149",
                    "ticker_sentiment_score": "0.331628",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.098255",
                    "ticker_sentiment_score": "0.210396",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board",
            "url": "https://www.globenewswire.com/news-release/2024/04/04/2857656/0/en/NextCure-Appoints-Dr-Rakesh-Dixit-to-Scientific-Advisory-Board.html",
            "time_published": "20240404T110500",
            "authors": [
                "NextCure"
            ],
            "summary": "BELTSVILLE, Md., April 04, 2024 ( GLOBE NEWSWIRE ) -- NextCure, Inc. ( Nasdaq: NXTC ) , a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/df24cd65-0f3d-4ede-9e7a-c3f58ce6e9d4",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.162362,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.130217",
                    "ticker_sentiment_score": "0.237163",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NXTC",
                    "relevance_score": "0.318074",
                    "ticker_sentiment_score": "0.042725",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.065327",
                    "ticker_sentiment_score": "0.201503",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Time to Tap Healthcare ETFs on Nvidia's AI Ambition?",
            "url": "https://www.zacks.com/stock/news/2250231/time-to-tap-healthcare-etfs-on-nvidias-ai-ambition",
            "time_published": "20240404T110000",
            "authors": [
                "Sanghamitra Saha"
            ],
            "summary": "At Nvidia's last week's GTC AI conference, the company announced partnerships in the healthcare sector, representing a strategic move toward expanding its revenue streams beyond tech sectors.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/75/44765.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.795202"
                }
            ],
            "overall_sentiment_score": 0.194563,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MCO",
                    "relevance_score": "0.084423",
                    "ticker_sentiment_score": "-0.048706",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RXRX",
                    "relevance_score": "0.167904",
                    "ticker_sentiment_score": "0.103476",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SDGR",
                    "relevance_score": "0.084423",
                    "ticker_sentiment_score": "0.072671",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.249531",
                    "ticker_sentiment_score": "0.152713",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Will Johnson & Johnson  ( JNJ )  Beat Estimates Again in Its Next Earnings Report?",
            "url": "https://www.zacks.com/stock/news/2249996/will-johnson-johnson-jnj-beat-estimates-again-in-its-next-earnings-report",
            "time_published": "20240403T161014",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default279.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99989"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.351386,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.402618",
                    "ticker_sentiment_score": "0.498513",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Robust Growth Expected In The Intestinal Pseudo Obstruction Treatment Market: Market To Grow At A Rate Of More Than 5% Through 2024-2028 As Per TBRC's Intestinal Pseudo Obstruction Treatment Global Market Report 2024",
            "url": "https://www.benzinga.com/pressreleases/24/04/g38072443/robust-growth-expected-in-the-intestinal-pseudo-obstruction-treatment-market-market-to-grow-at-a-r",
            "time_published": "20240403T153000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LONDON, April 03, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Intestinal Pseudo Obstruction Treatment Global Market Report 2024, the intestinal pseudo obstruction treatment market has witnessed strong growth in recent years, with the market size projected to increase from ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.130422,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VECT",
                    "relevance_score": "0.053271",
                    "ticker_sentiment_score": "0.063021",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARDX",
                    "relevance_score": "0.053271",
                    "ticker_sentiment_score": "0.063021",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IRWD",
                    "relevance_score": "0.053271",
                    "ticker_sentiment_score": "0.063021",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.053271",
                    "ticker_sentiment_score": "0.063021",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.053271",
                    "ticker_sentiment_score": "0.063021",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Transformative Growth Expected In The Global Medical Equipment Market: Market Size To Reach $1,077 Billion By 2028 As Per The Business Research Company's Medical Equipment Global Market Report 2024",
            "url": "https://www.benzinga.com/pressreleases/24/04/g38072444/transformative-growth-expected-in-the-global-medical-equipment-market-market-size-to-reach-1-077-b",
            "time_published": "20240403T153000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LONDON, April 03, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Medical Equipment Global Market Report 2024, the medical equipment market has witnessed robust growth in recent years, with the market size expected to reach $775.42 billion in 2024, reflecting a compound annual ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.338179,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GEHC",
                    "relevance_score": "0.05133",
                    "ticker_sentiment_score": "0.299729",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.05133",
                    "ticker_sentiment_score": "0.126428",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.05133",
                    "ticker_sentiment_score": "0.126428",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.05133",
                    "ticker_sentiment_score": "0.126428",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "5 Things to Know in Investing This Week - Boston Scientific  ( NYSE:BSX ) , Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/news/24/04/38056085/5-things-to-know-in-investing-this-week",
            "time_published": "20240403T142328",
            "authors": [
                "Gary Brode"
            ],
            "summary": "The Personal Consumption Expenditures ( PCE ) Index is the preferred inflation metric for the Federal Reserve. This month's report came out during Good Friday when the markets are closed. Within hours, the hawks who favor higher rates and the doves who favor lower rates all claimed the report ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/02/jason-briscoe-amlfrl8lgls-unsplash.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999499"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.118043,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SSNLF",
                    "relevance_score": "0.046363",
                    "ticker_sentiment_score": "0.163746",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.183895",
                    "ticker_sentiment_score": "0.131461",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NHNCF",
                    "relevance_score": "0.023191",
                    "ticker_sentiment_score": "0.135674",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.046363",
                    "ticker_sentiment_score": "0.053992",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.138464",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.046363",
                    "ticker_sentiment_score": "-0.074226",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Major shareholder announcement - Swedbank Robur Fonder AB",
            "url": "https://www.globenewswire.com/news-release/2024/04/03/2857099/0/en/Major-shareholder-announcement-Swedbank-Robur-Fonder-AB.html",
            "time_published": "20240403T140500",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.124283,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.303175",
                    "ticker_sentiment_score": "0.088424",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.303175",
                    "ticker_sentiment_score": "0.088424",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.303175",
                    "ticker_sentiment_score": "0.088424",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
            "url": "https://www.zacks.com/stock/news/2249582/these-2-medical-stocks-could-beat-earnings-why-they-should-be-on-your-radar",
            "time_published": "20240403T125011",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default249.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999973"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.38715,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.32478",
                    "ticker_sentiment_score": "0.367629",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVAX",
                    "relevance_score": "0.262522",
                    "ticker_sentiment_score": "0.315499",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Great Place To Work unveils Top 10 Best Workplaces in Singapore Healthcare and Biopharma™ 2024 - PR Newswire",
            "url": "https://www.prnewswire.com/apac/news-releases/great-place-to-work-unveils-top-10-best-workplaces-in-singapore-healthcare-and-biopharma-2024-302105205.html",
            "time_published": "20240403T040000",
            "authors": [],
            "summary": "Great Place To Work unveils Top 10 Best Workplaces in Singapore Healthcare and Biopharma™ 2024 PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.585696,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ALC",
                    "relevance_score": "0.108958",
                    "ticker_sentiment_score": "0.195043",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.054607",
                    "ticker_sentiment_score": "0.347092",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.108958",
                    "ticker_sentiment_score": "0.200563",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.054607",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.108958",
                    "ticker_sentiment_score": "0.152036",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Johnson & Johnson  ( JNJ )  Stock Moves -0.03%: What You Should Know",
            "url": "https://www.zacks.com/stock/news/2249380/johnson-johnson-jnj-stock-moves--003-what-you-should-know",
            "time_published": "20240402T214521",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The latest trading day saw Johnson & Johnson (JNJ) settling at $157.73, representing a -0.03% change from its previous close.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default97.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.986564"
                }
            ],
            "overall_sentiment_score": 0.122368,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.568651",
                    "ticker_sentiment_score": "0.109284",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation",
            "url": "https://www.globenewswire.com/news-release/2024/04/02/2856479/0/en/Nanobiotix-Announces-Completion-of-Phase-1-Dose-Escalation-and-NBTXR3-Recommended-Phase-2-Dose-for-the-Treatment-of-Inoperable-Recurrent-Lung-Cancer-in-Patients-Amenable-to-Re-Irra.html",
            "time_published": "20240402T201500",
            "authors": [
                "Nanobiotix S.A."
            ],
            "summary": "PARIS and CAMBRIDGE, Mass., April 02, 2024 ( GLOBE NEWSWIRE ) -- NANOBIOTIX ( Euronext : NANO -- NASDAQ: NBTX - the ''Company'' ) , a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/36fb7b98-27d7-46cb-b989-fa31626657b8",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.081771,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NBTX",
                    "relevance_score": "0.44802",
                    "ticker_sentiment_score": "0.030056",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.029654",
                    "ticker_sentiment_score": "0.045825",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:NANO",
                    "relevance_score": "0.029654",
                    "ticker_sentiment_score": "-0.049666",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Cytokine Market Size is projected to reach USD 148.56 billion by 2031, growing at a CAGR of 8.40%: Straits Research",
            "url": "https://www.benzinga.com/pressreleases/24/04/g38049628/cytokine-market-size-is-projected-to-reach-usd-148-56-billion-by-2031-growing-at-a-cagr-of-8-40-st",
            "time_published": "20240402T144000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "New York, United States, April 02, 2024 ( GLOBE NEWSWIRE ) -- A cytokine is a collection of proteins, peptides, or glycoproteins released by particular cells to regulate the development and function of the immune system and blood cells.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.00724,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.035875",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PTAIF",
                    "relevance_score": "0.035875",
                    "ticker_sentiment_score": "-0.067573",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.035875",
                    "ticker_sentiment_score": "-0.067573",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.035875",
                    "ticker_sentiment_score": "-0.067573",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UCBJF",
                    "relevance_score": "0.035875",
                    "ticker_sentiment_score": "-0.067573",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.035875",
                    "ticker_sentiment_score": "-0.067573",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.071677",
                    "ticker_sentiment_score": "-0.046635",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "AI ETFs: Q1 of 2024 Update",
            "url": "https://www.zacks.com/stock/news/2248900/ai-etfs-q1-of-2024-update",
            "time_published": "20240402T120000",
            "authors": [
                "Sanghamitra Saha"
            ],
            "summary": "The year 2023 was crucial in the Artificial Intelligence (AI) industry. So far this year, we have seen Apple's efforts to join the AI race more prudently, Amazon's billion dollar investment in AI start-up and Nvidia's efforts to foray into various industries with AI initiatives.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d9/21892.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.891286"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.282198,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.210274",
                    "ticker_sentiment_score": "0.295187",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.261117",
                    "ticker_sentiment_score": "0.264051",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.359262",
                    "ticker_sentiment_score": "0.245994",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.261117",
                    "ticker_sentiment_score": "0.2589",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.10607",
                    "ticker_sentiment_score": "0.048514",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why 3M Stock Was Moving Higher Today",
            "url": "https://www.fool.com/investing/2024/04/01/why-3m-stock-was-moving-higher-today/",
            "time_published": "20240401T210643",
            "authors": [
                "Jeremy Bowman"
            ],
            "summary": "Investors applauded the spin-off of its healthcare business.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771486%2F3m-st-paul-monument-place001-rgb-1.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.2628,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.138464",
                    "ticker_sentiment_score": "0.006257",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KD",
                    "relevance_score": "0.138464",
                    "ticker_sentiment_score": "0.006257",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.138464",
                    "ticker_sentiment_score": "0.006257",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Reasons You Can Buy This \"Magnificent Seven\" Stock and Hold It Forever",
            "url": "https://www.fool.com/investing/2024/04/01/3-reasons-you-can-buy-this-magnificent-seven-stock/",
            "time_published": "20240401T150000",
            "authors": [
                "Justin Pope"
            ],
            "summary": "Buy and hold forever is a bold ask. However, Microsoft delivers across the board.",
            "banner_image": "https://g.foolcdn.com/editorial/images/770918/msft-3.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.252095,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.717458",
                    "ticker_sentiment_score": "0.370799",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.071357",
                    "ticker_sentiment_score": "0.302099",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.071357",
                    "ticker_sentiment_score": "0.140933",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Looking Into Johnson & Johnson's Recent Short Interest - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/insights/short-sellers/24/04/38024239/looking-into-johnson-johnsons-recent-short-interest",
            "time_published": "20240401T143020",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Johnson & Johnson's JNJ short percent of float has risen 6.45% since its last report. The company recently reported that it has 15.84 million shares sold short, which is 0.66% of all regular shares that are available for trading.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.287737,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.209365",
                    "ticker_sentiment_score": "0.147012",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Reasons to Add ShockWave Medical  ( SWAV )  to Your Portfolio Now",
            "url": "https://www.zacks.com/stock/news/2248484/reasons-to-add-shockwave-medical-swav-to-your-portfolio-now",
            "time_published": "20240401T140100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.890401"
                }
            ],
            "overall_sentiment_score": 0.323832,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CAH",
                    "relevance_score": "0.166935",
                    "ticker_sentiment_score": "0.093567",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ITGR",
                    "relevance_score": "0.221313",
                    "ticker_sentiment_score": "0.18704",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.111747",
                    "ticker_sentiment_score": "0.06145",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.377142",
                    "ticker_sentiment_score": "0.514119",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.056011",
                    "ticker_sentiment_score": "0.006001",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Spectral AI Appoints Jeremiah Sparks as Chief Commercialization Officer",
            "url": "https://www.globenewswire.com/news-release/2024/04/01/2855212/0/en/Spectral-AI-Appoints-Jeremiah-Sparks-as-Chief-Commercialization-Officer.html",
            "time_published": "20240401T130000",
            "authors": [
                "Spectral AI",
                "Inc."
            ],
            "summary": "Experienced Burn Industry Executive Champions Pivot to Commercialization Experienced Burn Industry Executive Champions Pivot to Commercialization ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/a9a72c47-e800-49a2-a556-205f5f53d330",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.250795,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "RCEL",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.09503",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.052685",
                    "ticker_sentiment_score": "0.133004",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDAI",
                    "relevance_score": "0.2589",
                    "ticker_sentiment_score": "0.31291",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "United Airlines Names Michelle Freyre to Board of Directors - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/united-airlines-names-michelle-freyre-to-board-of-directors-302104454.html",
            "time_published": "20240401T121400",
            "authors": [],
            "summary": "United Airlines Names Michelle Freyre to Board of Directors PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.477085,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SKYW",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UAL",
                    "relevance_score": "0.528475",
                    "ticker_sentiment_score": "0.541368",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "ERJ",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.063763",
                    "ticker_sentiment_score": "0.059024",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 VALIC Mutual Funds for Consistent Returns",
            "url": "https://www.zacks.com/stock/news/2248136/3-valic-mutual-funds-for-consistent-returns",
            "time_published": "20240401T105200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Invests in VALIC Mutual Funds like VCAAX, VCULX and VBCVX for tax-efficient wealth growth.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a8/346.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.271059,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.136113",
                    "ticker_sentiment_score": "0.057482",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.136113",
                    "ticker_sentiment_score": "0.057482",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRBG",
                    "relevance_score": "0.068306",
                    "ticker_sentiment_score": "0.034073",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.068306",
                    "ticker_sentiment_score": "0.048112",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.068306",
                    "ticker_sentiment_score": "0.048112",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Meet The Billionaire Bond Investor Behind Chelsea F.C., Springsteen's Songbook And The LA Dodgers",
            "url": "https://www.forbes.com/sites/maneetahuja/2024/04/01/meet-the-billionaire-bond-trader-behind-chelsea-fc-springsteens-songbook-and-the-la-dodgers/",
            "time_published": "20240401T103000",
            "authors": [
                "Maneet Ahuja"
            ],
            "summary": "Meet The Billionaire Bond Trader Behind Chelsea F.C., Springsteen's Songbook And The LA Dodgers Forbes ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6606ec6b7bb3d8b0c846fbf2/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.151857,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.025008",
                    "ticker_sentiment_score": "0.043599",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.012506",
                    "ticker_sentiment_score": "0.166244",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.012506",
                    "ticker_sentiment_score": "0.127766",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.012506",
                    "ticker_sentiment_score": "0.050837",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.025008",
                    "ticker_sentiment_score": "0.051538",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "WM Phoenix Open Delivers Refunds To About 2,800 Fans After Ticket Snafu",
            "url": "https://www.forbes.com/sites/jackmagruder/2024/03/31/wm-phoenix-open-delivers-refunds-to-about-2800-fans-after-ticket-snafu/",
            "time_published": "20240331T214307",
            "authors": [
                "Jack Magruder"
            ],
            "summary": "The \"People's Open\" is attempting to make its people whole. The WM Phoenix Open - which bills itself as the People's Open because of the overwhelming support it receives from the local golf community - has given refunds to about 2,800 ticket holders who were denied entrance to the third round of ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6609d2136f8e76d5f31c49d4/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.007244,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.062434",
                    "ticker_sentiment_score": "-0.171128",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "2024 S&P 500 Bull Market: 2 Unstoppable Growth Stocks to Buy Right Now",
            "url": "https://www.fool.com/investing/2024/03/31/2024-sp-500-bull-market-2-unstoppable-growth-stock/",
            "time_published": "20240331T071000",
            "authors": [
                "Rachel Warren"
            ],
            "summary": "The fresh bull market is attracting investors of all trading styles.",
            "banner_image": "https://g.foolcdn.com/editorial/images/770831/getty-listening-learning-headphones-laptop-notes-studying.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999995"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.26699,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.040899",
                    "ticker_sentiment_score": "0.069513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JCI",
                    "relevance_score": "0.040899",
                    "ticker_sentiment_score": "0.15753",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.461699",
                    "ticker_sentiment_score": "0.337535",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.241684",
                    "ticker_sentiment_score": "0.260649",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "3 Reliable Dividend Growth Stocks With Yields Above 3% That You Can Buy Now and Hold for at Least a Decade",
            "url": "https://www.fool.com/investing/2024/03/30/3-reliable-dividend-growth-stocks-with-yields-abov/",
            "time_published": "20240330T091900",
            "authors": [
                "Cory Renauer"
            ],
            "summary": "These advantaged businesses have what it takes to keep raising their payouts.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F770568%2Fgroup-of-investors-looking-at-charts.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.967321"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                }
            ],
            "overall_sentiment_score": 0.238472,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.146916",
                    "ticker_sentiment_score": "-0.045412",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.098255",
                    "ticker_sentiment_score": "0.049573",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.049221",
                    "ticker_sentiment_score": "0.133067",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.098255",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Titan Medical Reports Fiscal Year 2023 Results",
            "url": "https://www.globenewswire.com/news-release/2024/03/29/2854853/0/en/Titan-Medical-Reports-Fiscal-Year-2023-Results.html",
            "time_published": "20240329T214100",
            "authors": [
                "Titan Medical Inc."
            ],
            "summary": "TORONTO, Ontario, March 29, 2024 ( GLOBE NEWSWIRE ) -- Titan Medical Inc. ( \"Titan\" or the \"Company\" ) ( TSX: TMD. OTC: TMDIF ) , today reported financial results for the fiscal year ended December 31, 2023.",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/e9df9371-cb74-4840-8337-d9d5faea1dce",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.271129,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MDT",
                    "relevance_score": "0.107016",
                    "ticker_sentiment_score": "0.2279",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.035768",
                    "ticker_sentiment_score": "0.157169",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TMDIF",
                    "relevance_score": "0.142355",
                    "ticker_sentiment_score": "0.211099",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Microsoft, Salesforce woo skeptical CFOs on new generative AI tool spending",
            "url": "https://www.cnbc.com/2024/03/29/microsoft-salesforce-woo-skeptical-cfos-on-new-generative-ai-spending.html",
            "time_published": "20240329T142858",
            "authors": [
                "Ian Thomas"
            ],
            "summary": "Salesforce and Microsoft are among the enterprise software giants trying to convince hesitant CFOs to spend on new finance-focused generative AI tools.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107379577-17091270721709127069-33512186519-1080pnbcnews.jpg?v=1709127071&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.189886,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "FCN",
                    "relevance_score": "0.034282",
                    "ticker_sentiment_score": "0.032331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.068502",
                    "ticker_sentiment_score": "0.11942",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.034282",
                    "ticker_sentiment_score": "0.117293",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TRMNF",
                    "relevance_score": "0.034282",
                    "ticker_sentiment_score": "0.059182",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.034282",
                    "ticker_sentiment_score": "0.117293",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here is What to Know Beyond Why Johnson & Johnson  ( JNJ )  is a Trending Stock",
            "url": "https://www.zacks.com/stock/news/2247838/here-is-what-to-know-beyond-why-johnson-johnson-jnj-is-a-trending-stock",
            "time_published": "20240329T130016",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default338.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.5855"
                }
            ],
            "overall_sentiment_score": 0.23546,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.47147",
                    "ticker_sentiment_score": "0.164529",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why Shockwave Medical Stock Rallied as Much as 18% Higher This Week",
            "url": "https://www.fool.com/investing/2024/03/29/why-shockwave-medical-stock-rallied-as-much-as-18/",
            "time_published": "20240329T130000",
            "authors": [
                "Danny Vena"
            ],
            "summary": "Buyout rumors and love from Wall Street propelled the stock to double-digit gains.",
            "banner_image": "https://g.foolcdn.com/editorial/images/771112/a-surgeon-looking-at-a-patient-on-the-operating-table-during-a-robotic-surgical-procedure.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.94762"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.202315,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.10607",
                    "ticker_sentiment_score": "0.044059",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.576289",
                    "ticker_sentiment_score": "0.161959",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.406197",
                    "ticker_sentiment_score": "0.033564",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "5 New Advancements In AI And Web3: Base, Meme Coins, Bitcoin Halving",
            "url": "https://www.forbes.com/sites/digital-assets/2024/03/28/5-new-advancements-in-ai-and-web3-meme-coins-base-bitcoin-halving/",
            "time_published": "20240328T171722",
            "authors": [
                "Sandy Carter"
            ],
            "summary": "In Lewis Carroll's classic, \"Alice in Wonderland,\" the Red Queen tells Alice that in her kingdom, \"it takes all the running you can do, to keep in the same place.\" This vivid metaphor is apt for the current pace of technological change, particularly in the realms of artificial intelligence ( AI ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6605a18c9f4dbfe5587f0b07/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.928139"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.354778,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.020722",
                    "ticker_sentiment_score": "0.091847",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.020722",
                    "ticker_sentiment_score": "0.157557",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.020722",
                    "ticker_sentiment_score": "0.141321",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COIN",
                    "relevance_score": "0.103331",
                    "ticker_sentiment_score": "0.203954",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HCSG",
                    "relevance_score": "0.020722",
                    "ticker_sentiment_score": "0.240372",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.020722",
                    "ticker_sentiment_score": "0.157557",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.204936",
                    "ticker_sentiment_score": "0.14067",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:ETH",
                    "relevance_score": "0.04143",
                    "ticker_sentiment_score": "0.199168",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRYPTO:SHIB",
                    "relevance_score": "0.020722",
                    "ticker_sentiment_score": "0.062256",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:DOGE",
                    "relevance_score": "0.06211",
                    "ticker_sentiment_score": "0.10225",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson Has An Opportunity In Talc-Cancer Lawsuit, Can Challenge Scientific Evidence In Federal Ruling - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37989675/johnson-johnson-has-an-opportunity-in-talc-cancer-lawsuit-can-challenge-scientific-evidence-in-fe",
            "time_published": "20240328T165836",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Johnson & Johnson JNJ reportedly has an opportunity to challenge the scientific evidence linking talc to ovarian cancer, as U.S. District Judge Michael Shipp ruled on Wednesday.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/johnsons-5671315-1920_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.172029,
            "overall_sentiment_label": "Somewhat-Bearish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.464633",
                    "ticker_sentiment_score": "-0.172691",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Shockwave Medical  ( SWAV )  Up on Potential Acquisition Rumors",
            "url": "https://www.zacks.com/stock/news/2247467/shockwave-medical-swav-up-on-potential-acquisition-rumors",
            "time_published": "20240328T140200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Shockwave Medical's (SWAV) shares gain as rumors about its potential acquisition by an industry giant get media attention.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.838487"
                }
            ],
            "overall_sentiment_score": 0.273013,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CAH",
                    "relevance_score": "0.215574",
                    "ticker_sentiment_score": "0.058873",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.072655",
                    "ticker_sentiment_score": "0.187663",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SYK",
                    "relevance_score": "0.144708",
                    "ticker_sentiment_score": "0.079357",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.072655",
                    "ticker_sentiment_score": "0.187663",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.684158",
                    "ticker_sentiment_score": "0.438425",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.284696",
                    "ticker_sentiment_score": "0.228902",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors - Compass Pathways  ( NASDAQ:CMPS ) ",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37980064/compass-pathways-board-chair-and-co-founder-george-goldsmith-and-co-founder-ekaterina-malievskaia-",
            "time_published": "20240328T120000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LONDON, March 28, 2024 ( GLOBE NEWSWIRE ) -- Compass Pathways plc CMPS ( \"Compass\" ) , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that Board Chair and co-founder George Goldsmith and fellow co-founder Ekaterina ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.168879,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CMPS",
                    "relevance_score": "0.212348",
                    "ticker_sentiment_score": "0.273889",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.02686",
                    "ticker_sentiment_score": "0.01886",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "4 Best ETF Areas of Q1",
            "url": "https://www.zacks.com/stock/news/2247146/4-best-etf-areas-of-q1",
            "time_published": "20240328T120000",
            "authors": [
                "Sanghamitra Saha"
            ],
            "summary": "Wall Street is poised to conclude the first quarter with robust gains due to a likely dovish Fed and robust economic as well as earnings growth.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/1a/2589.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99246"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.139292,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.062271",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.073384",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.303926",
                    "ticker_sentiment_score": "0.111528",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:ETH",
                    "relevance_score": "0.124164",
                    "ticker_sentiment_score": "0.075688",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Dividend Stocks That Are Likely to Raise Their Payouts in April",
            "url": "https://www.fool.com/investing/2024/03/28/3-dividend-stocks-that-are-likely-to-raise-their/",
            "time_published": "20240328T101500",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Dividend increases should soon be coming from these stocks, but be careful -- it doesn't mean all of them are great buys.",
            "banner_image": "https://g.foolcdn.com/editorial/images/770398/a-person-smiling-and-reviewing-their-finances.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999922"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                }
            ],
            "overall_sentiment_score": 0.274728,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "COST",
                    "relevance_score": "0.2842",
                    "ticker_sentiment_score": "0.272521",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.337811",
                    "ticker_sentiment_score": "0.175008",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.229149",
                    "ticker_sentiment_score": "0.24583",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "J&J can contest evidence linking its talc to ovarian cancer, says US judge",
            "url": "https://www.business-standard.com/world-news/j-j-can-contest-evidence-linking-its-talc-to-ovarian-cancer-says-us-judge-124032800100_1.html",
            "time_published": "20240328T031249",
            "authors": [
                "Reuters"
            ],
            "summary": "Johnson & Johnson will get a new chance to contest the scientific evidence linking talc to ovarian cancer, a federal judge ruled on Wednesday, potentially disrupting more than 53,000 lawsuits the company is now facing over its talc products. In a brief written order, U.S.",
            "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2023-12/05/full/1701794396-0294.jpg?im=FeatureCrop,size=(826,465)",
            "source": "Business Standard",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.business-standard.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.11087,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "PFE",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "-0.096292",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "-0.101187",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "-0.096292",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Bernie Sanders Calls On Novo Nordisk To Lower Cost Of Ozempic And Wegovy",
            "url": "https://www.forbes.com/sites/saradorn/2024/03/27/bernie-sanders-calls-on-novo-nordisk-to-lower-cost-of-ozempic-and-wegovy/",
            "time_published": "20240327T211855",
            "authors": [
                "Sara Dorn"
            ],
            "summary": "Sen. Bernie Sanders, I-Vt., demanded Novo Nordisk, the Danish drug company that manufactures the wildly popular Ozempic and Wegovy weight loss drugs, lower the list price of the drugs, warning the \"outrageously high price has the potential to bankrupt Medicare, the American people and our entire ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/66048cd417ea5d90971467a4/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": -0.055049,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "NYT",
                    "relevance_score": "0.062271",
                    "ticker_sentiment_score": "0.052093",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.245339",
                    "ticker_sentiment_score": "-0.071817",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.062271",
                    "ticker_sentiment_score": "-0.053135",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.062271",
                    "ticker_sentiment_score": "-0.053135",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson Strong Strategic Fit For Shockwave Medical, But Medtronic, Boston Scientific Could Be Other Bidder, Says Analyst - Boston Scientific  ( NYSE:BSX ) , Johnson & Johnson  ( NYSE:JNJ ) , Medtronic  ( NYSE:MDT ) , Shockwave Medical  ( NASDAQ:SWAV ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37970454/johnson-johnson-strong-strategic-fit-for-shockwave-medical-but-medtronic-boston-sci",
            "time_published": "20240327T202327",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Tuesday, Shockwave Medical Inc SWAV shares traded higher following a Wall Street Journal report suggesting Johnson & Johnson JNJ is reportedly in talks to acquire the company. Shockwave Medical is a cardiovascular medical device.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Johnson-and-Johnson_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.311393,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MDT",
                    "relevance_score": "0.331765",
                    "ticker_sentiment_score": "0.448714",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.331765",
                    "ticker_sentiment_score": "0.448714",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.883917",
                    "ticker_sentiment_score": "0.4855",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.608634",
                    "ticker_sentiment_score": "0.494139",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Shockwave Medical Stock Sees Relative Strength Rating Ride Higher",
            "url": "https://www.investors.com/news/shockwave-medical-stock-sees-relative-strength-rating-ride-higher/",
            "time_published": "20240327T190700",
            "authors": [
                "Investor's Business Daily",
                "INVESTOR'S BUSINESS DAILY",
                "JULIE MAK"
            ],
            "summary": "On Wednesday, Shockwave Medical ( SWAV ) stock got a positive adjustment to its Relative Strength ( RS ) Rating, from 90 to 94. The stock has been rallying amid a Wall Street Journal report that Johnson and Johnson ( JNJ ) is in talks to buy Shockwave Medical.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU5.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.980922"
                }
            ],
            "overall_sentiment_score": 0.36848,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BRKR",
                    "relevance_score": "0.290607",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.147818",
                    "ticker_sentiment_score": "0.221919",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.543935",
                    "ticker_sentiment_score": "0.332553",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.290607",
                    "ticker_sentiment_score": "0.332694",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Neptune Strengthens Americas Sales Leadership with the Appointment of Jeff Piszczek as Vice President - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/neptune-strengthens-americas-sales-leadership-with-the-appointment-of-jeff-piszczek-as-vice-president-302101233.html",
            "time_published": "20240327T150400",
            "authors": [],
            "summary": "Neptune Strengthens Americas Sales Leadership with the Appointment of Jeff Piszczek as Vice President PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.466435,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.077593",
                    "ticker_sentiment_score": "0.20629",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SWDAF",
                    "relevance_score": "0.077593",
                    "ticker_sentiment_score": "0.204196",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Merck  ( MRK )  Gets FDA Approval for New PAH Drug Winrevair",
            "url": "https://www.zacks.com/stock/news/2246486/merck-mrk-gets-fda-approval-for-new-pah-drug-winrevair",
            "time_published": "20240327T123900",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Merck's (MRK) Winrevair becomes the first novel activin signaling inhibitor approved by the FDA to treat PAH.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.261248,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ADMA",
                    "relevance_score": "0.38588",
                    "ticker_sentiment_score": "0.333986",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UTHR",
                    "relevance_score": "0.199037",
                    "ticker_sentiment_score": "0.271387",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.13347",
                    "ticker_sentiment_score": "0.211276",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields - Johnson & Johnson  ( NYSE:JNJ ) , Gilead Sciences  ( NASDAQ:GILD ) ",
            "url": "https://www.benzinga.com/news/24/03/37956052/wall-streets-most-accurate-analysts-views-on-3-health-care-stocks-delivering-high-dividend-yields",
            "time_published": "20240327T121334",
            "authors": [
                "Avi Kapoor"
            ],
            "summary": "During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/27/image45.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.124976,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GILD",
                    "relevance_score": "0.116914",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PDCO",
                    "relevance_score": "0.116914",
                    "ticker_sentiment_score": "0.225123",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.116914",
                    "ticker_sentiment_score": "-0.078277",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.231332",
                    "ticker_sentiment_score": "-0.121238",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.231332",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.116914",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Bank Of America Bullish On AI: Spotlights Top Supply Chain Stocks To Watch - NVIDIA  ( NASDAQ:NVDA ) , Alchip Techs  ( OTC:ALCPF ) ",
            "url": "https://www.benzinga.com/markets/equities/24/03/37950500/bank-of-america-bullish-on-ai-spotlights-top-supply-chain-stocks-to-watch",
            "time_published": "20240327T025648",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "Bank of America has identified key global stocks along the AI supply chain, including several NVIDIA Corp NVDA suppliers poised to benefit from the AI boom. What Happened: BofA highlighted the booming AI market and the potential for smaller firms in the global AI supply chain to benefit, reported ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Nvidia-Money-Shutterstock_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.237811,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.504646",
                    "ticker_sentiment_score": "0.126314",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PWR",
                    "relevance_score": "0.214937",
                    "ticker_sentiment_score": "0.280779",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.108466",
                    "ticker_sentiment_score": "0.284086",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GE",
                    "relevance_score": "0.108466",
                    "ticker_sentiment_score": "0.21569",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.108466",
                    "ticker_sentiment_score": "0.21569",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why the Market Dipped But Johnson & Johnson  ( JNJ )  Gained Today",
            "url": "https://www.zacks.com/stock/news/2246287/why-the-market-dipped-but-johnson-johnson-jnj-gained-today",
            "time_published": "20240326T214521",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "In the latest trading session, Johnson & Johnson (JNJ) closed at $155.77, marking a +0.35% move from the previous day.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default34.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.972476"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.122893,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.628699",
                    "ticker_sentiment_score": "0.126454",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "FDA approves new drug that may help stop and even reverse a rare, fatal condition that doctors call a 'ticking time bomb'",
            "url": "https://www.cnn.com/2024/03/26/health/winrevair-pah-drug-approval/index.html",
            "time_published": "20240326T210600",
            "authors": [
                "Brenda Goodman"
            ],
            "summary": "When doctors told Katrina Barry that she had a rare and serious condition called pulmonary arterial hypertension or PAH, they warned her not to Google it. Come on, she thought.",
            "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/20240326-merck-drug.jpg?q=w_1110,c_fill",
            "source": "CNN",
            "category_within_source": "Markets",
            "source_domain": "www.cnn.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.092801,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "WBD",
                    "relevance_score": "0.017638",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.017638",
                    "ticker_sentiment_score": "0.187748",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "What's Going On With Shockwave Medical Stock? - Shockwave Medical  ( NASDAQ:SWAV ) ",
            "url": "https://www.benzinga.com/news/24/03/37945385/whats-going-on-with-shockwave-medical-stock",
            "time_published": "20240326T195358",
            "authors": [
                "Erica Kollmann"
            ],
            "summary": "Shockwave Medical, Inc. SWAV shares are trading higher Tuesday following a report suggesting Johnson & Johnson JNJ is in talks to acquire the company. According to a report from the Wall Street Journal, people familiar with the matter say that a deal to acquire the company could be completed in ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/pulse-cardio.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.240621,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SWAV",
                    "relevance_score": "0.841002",
                    "ticker_sentiment_score": "0.321853",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.221819",
                    "ticker_sentiment_score": "0.174066",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Should You Invest in the iShares U.S. Healthcare ETF  ( IYH ) ?",
            "url": "https://www.zacks.com/stock/news/2245797/should-you-invest-in-the-ishares-us-healthcare-etf-iyh",
            "time_published": "20240326T102006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sector ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default11.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.219275,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.066414",
                    "ticker_sentiment_score": "0.088153",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.132368",
                    "ticker_sentiment_score": "0.069712",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.132368",
                    "ticker_sentiment_score": "0.069712",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.132368",
                    "ticker_sentiment_score": "0.069712",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Assessing Johnson & Johnson's Performance Against Competitors In Pharmaceuticals Industry - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/insights/news/24/03/37917519/assessing-johnson-amp-johnsons-performance-against-competitors-in-pharmaceuticals-industry",
            "time_published": "20240325T160051",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Johnson & Johnson JNJ in comparison to its major competitors within the ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.961735"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.225598,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.062434",
                    "ticker_sentiment_score": "0.139073",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.416516",
                    "ticker_sentiment_score": "0.287954",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Nvidia's AI Revolution Is Transforming Healthcare with Johnson & Johnson and GE Healthcare Partnerships - NVIDIA  ( NASDAQ:NVDA ) ",
            "url": "https://www.benzinga.com/news/24/03/37916877/nvidias-ai-revolution-is-transforming-healthcare-with-johnson-johnson-and-ge-healthcare-partnerships",
            "time_published": "20240325T153147",
            "authors": [
                "Anusuya Lahiri"
            ],
            "summary": "Last week, Nvidia Corp NVDA announced significant collaborations with Johnson & Johnson JNJ and General Electric Co GE GE Healthcare to integrate generative AI into surgery and enhance medical imaging.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Artificial-Intelligence-Photo-by-Pixels-_4.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.201614,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AMD",
                    "relevance_score": "0.175859",
                    "ticker_sentiment_score": "0.072002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MCO",
                    "relevance_score": "0.088472",
                    "ticker_sentiment_score": "-0.069117",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.421485",
                    "ticker_sentiment_score": "0.376016",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "RXRX",
                    "relevance_score": "0.175859",
                    "ticker_sentiment_score": "0.108268",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GE",
                    "relevance_score": "0.261117",
                    "ticker_sentiment_score": "0.324991",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.175859",
                    "ticker_sentiment_score": "0.243267",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "GE HealthCare  ( GEHC )  Uses AI Solution to Boost Medical Imaging",
            "url": "https://www.zacks.com/stock/news/2245566/ge-healthcare-gehc-uses-ai-solution-to-boost-medical-imaging",
            "time_published": "20240325T142000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "GE HealthCare's (GEHC) SonoSAMTrack demonstrates its pliability and applicability in ultrasound image segmentation by using NVIDIA's technology.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.327917,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GEHC",
                    "relevance_score": "0.104002",
                    "ticker_sentiment_score": "0.084829",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.206245",
                    "ticker_sentiment_score": "0.156633",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HOLX",
                    "relevance_score": "0.206245",
                    "ticker_sentiment_score": "0.165448",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.206245",
                    "ticker_sentiment_score": "0.172415",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Should You Invest in the Health Care Select Sector SPDR ETF  ( XLV ) ?",
            "url": "https://www.zacks.com/stock/news/2245284/should-you-invest-in-the-health-care-select-sector-spdr-etf-xlv",
            "time_published": "20240325T102007",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sector ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default168.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.303397,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.063944",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.064276",
                    "ticker_sentiment_score": "0.127429",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "STT",
                    "relevance_score": "0.064276",
                    "ticker_sentiment_score": "0.089069",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.063944",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.128135",
                    "ticker_sentiment_score": "0.063944",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Nvidia's AI ambitions in medicine and health care are becoming clear",
            "url": "https://www.cnbc.com/2024/03/24/nvidias-ai-ambitions-in-medicine-and-health-care-are-becoming-clear.html",
            "time_published": "20240324T141834",
            "authors": [
                "Michelle Castillo"
            ],
            "summary": "Applying Nvidia AI chips to health care, whether it's biotechnology, chemicals, or drug discovery is going to be a big business.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107389777-1710888817MM-A-031924-short.jpg?v=1710888817&w=750&h=422&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.124784,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MCO",
                    "relevance_score": "0.042647",
                    "ticker_sentiment_score": "0.082902",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.443626",
                    "ticker_sentiment_score": "0.176278",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "RXRX",
                    "relevance_score": "0.042647",
                    "ticker_sentiment_score": "0.048418",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SDGR",
                    "relevance_score": "0.042647",
                    "ticker_sentiment_score": "0.048202",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WLDS",
                    "relevance_score": "0.042647",
                    "ticker_sentiment_score": "0.066259",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.042647",
                    "ticker_sentiment_score": "0.150241",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Want $1 Million in Retirement? 9 ETFs to Buy Now and Hold for Decades.",
            "url": "https://www.fool.com/investing/2024/03/24/want-million-retirement-etfs-buy-now-hold-decade/",
            "time_published": "20240324T093000",
            "authors": [
                "Selena Maranjian"
            ],
            "summary": "Parking some of your dollars in high-performing sector ETFs may juice your portfolio's returns.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F769398%2Fgetty-closeup-of-happy-smiling-freckled-face.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.183028,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSTR",
                    "relevance_score": "0.048133",
                    "ticker_sentiment_score": "0.084086",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.048133",
                    "ticker_sentiment_score": "0.113901",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.048133",
                    "ticker_sentiment_score": "0.113901",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.096091",
                    "ticker_sentiment_score": "0.030387",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.048133",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VZ",
                    "relevance_score": "0.048133",
                    "ticker_sentiment_score": "0.113901",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMCI",
                    "relevance_score": "0.048133",
                    "ticker_sentiment_score": "0.084086",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.048133",
                    "ticker_sentiment_score": "-0.068161",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.048133",
                    "ticker_sentiment_score": "0.120877",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.048133",
                    "ticker_sentiment_score": "0.120877",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.096091",
                    "ticker_sentiment_score": "0.030387",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LEN",
                    "relevance_score": "0.048133",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNP",
                    "relevance_score": "0.048133",
                    "ticker_sentiment_score": "0.10892",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GE",
                    "relevance_score": "0.048133",
                    "ticker_sentiment_score": "0.10892",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "U.S. FDA Approves OPSYNVI®  ( macitentan and tadalafil )  as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension  ( PAH ) ",
            "url": "https://www.prnewswire.com/news-releases/us-fda-approves-opsynvi-macitentan-and-tadalafil-as-the-first-and-only-once-daily-single-tablet-combination-therapy-for-patients-with-pulmonary-arterial-hypertension-pah-302097530.html",
            "time_published": "20240322T223500",
            "authors": [
                "Johnson & Johnson"
            ],
            "summary": "U.S. FDA Approves OPSYNVI® ( macitentan and tadalafil ) as the First and Only Once-Daily Single-Tablet Combination ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/2369753/JJ_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.107711,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.307603",
                    "ticker_sentiment_score": "0.107039",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/pharmaceuticals-market-in-germany-size-is-set-to-grow-by-usd-21-44-bn-from-2023-2027--abbott-laboratories-abbvie-inc--amgen-inc-and-more-to-emerge-as-some-of-the-key-vendors--technavio-302096253.html",
            "time_published": "20240322T161800",
            "authors": [],
            "summary": "Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.244345,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BAYZF",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BLCO",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "-0.020684",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TEVA",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.037387",
                    "ticker_sentiment_score": "0.099883",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Vaccine Market Insights Revealed in New 2024 Global Industry Report",
            "url": "https://www.prnewswire.com/news-releases/vaccine-market-insights-revealed-in-new-2024-global-industry-report-302095932.html",
            "time_published": "20240322T160000",
            "authors": [
                "Research and Markets"
            ],
            "summary": "DUBLIN, March 22, 2024 /PRNewswire/ -- The \"The World Market for Vaccines, 2024\" report has been added to ResearchAndMarkets.com's offering. The healthcare landscape is ever-evolving, and as infectious diseases continue to be a global concern, the vaccine market remains a critical area of focus ...",
            "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.167321,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.086556",
                    "ticker_sentiment_score": "0.088441",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.086556",
                    "ticker_sentiment_score": "0.088441",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.086556",
                    "ticker_sentiment_score": "0.088441",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.086556",
                    "ticker_sentiment_score": "0.088441",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "CIO Leadership: The Call for Cybersecurity Innovation will Power the Discussion at the 13th Annual Washington, D.C. C-Level Technology Leadership Summit on April 18",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37893536/cio-leadership-the-call-for-cybersecurity-innovation-will-power-the-discussion-at-the-13th-annual-",
            "time_published": "20240322T150836",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "WESTPORT, Conn., March 22, 2024 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 platform for enabling technology executives to reimagine the enterprise and reshape the business world, is thrilled to announce that its 13th Annual Washington, D.C.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.193392,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.01957",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UPWK",
                    "relevance_score": "0.039128",
                    "ticker_sentiment_score": "0.047481",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RNG",
                    "relevance_score": "0.058663",
                    "ticker_sentiment_score": "0.049171",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DRKTF",
                    "relevance_score": "0.058663",
                    "ticker_sentiment_score": "0.049171",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DTII",
                    "relevance_score": "0.01957",
                    "ticker_sentiment_score": "-0.055269",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RMNI",
                    "relevance_score": "0.078163",
                    "ticker_sentiment_score": "0.049587",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UTZ",
                    "relevance_score": "0.01957",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBGSF",
                    "relevance_score": "0.039128",
                    "ticker_sentiment_score": "0.041402",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KFY",
                    "relevance_score": "0.01957",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PANW",
                    "relevance_score": "0.117009",
                    "ticker_sentiment_score": "0.057343",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CL",
                    "relevance_score": "0.01957",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OMF",
                    "relevance_score": "0.01957",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PSN",
                    "relevance_score": "0.01957",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCO",
                    "relevance_score": "0.01957",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMG",
                    "relevance_score": "0.01957",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FUTU",
                    "relevance_score": "0.01957",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "APPN",
                    "relevance_score": "0.058663",
                    "ticker_sentiment_score": "0.049171",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NTNX",
                    "relevance_score": "0.058663",
                    "ticker_sentiment_score": "0.049171",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BACHY",
                    "relevance_score": "0.01957",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FTNT",
                    "relevance_score": "0.039128",
                    "ticker_sentiment_score": "0.047481",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALC",
                    "relevance_score": "0.01957",
                    "ticker_sentiment_score": "0.158266",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ZS",
                    "relevance_score": "0.058663",
                    "ticker_sentiment_score": "0.049171",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FUJIF",
                    "relevance_score": "0.01957",
                    "ticker_sentiment_score": "0.2265",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UPBD",
                    "relevance_score": "0.039128",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IDCBY",
                    "relevance_score": "0.01957",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Gaining An Edge: 5 AI-Powered Strategies For Stock Market Success",
            "url": "https://www.forbes.com/sites/investor/2024/03/22/gaining-an-edge-5-ai-powered-strategies-for-stock-market-success/",
            "time_published": "20240322T150602",
            "authors": [
                "John P. Reese"
            ],
            "summary": "In the fast-paced world of investing, staying ahead of the curve is crucial for success. As artificial intelligence ( AI ) continues to transform various industries, savvy investors are turning to AI-powered tools and strategies to gain a competitive advantage in the stock market.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65fd9dc3088caa9883857ceb/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.43189,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.047185",
                    "ticker_sentiment_score": "0.173575",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.047185",
                    "ticker_sentiment_score": "0.2056",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.047185",
                    "ticker_sentiment_score": "0.101253",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.047185",
                    "ticker_sentiment_score": "0.101253",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "GMO Quality Fund Aims To Beat Its Decade-Long Outperformance",
            "url": "https://www.investors.com/etfs-and-funds/mutual-funds/gmo-quality-fund-10-year-performance/",
            "time_published": "20240322T123048",
            "authors": [
                "ROBERT POWELL",
                "Investor's Business Daily"
            ],
            "summary": "Though past performance is not indicative of future results, the decade-long exceptional track record of the GMO Quality Fund - a top winner in Investor's Business Daily's 2024 Best Mutual Funds Awards - deserves some special attention.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2024/03/w.GMO032524eps-300x127.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.267603,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.111933",
                    "ticker_sentiment_score": "0.125738",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.064104",
                    "ticker_sentiment_score": "0.053132",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.032078",
                    "ticker_sentiment_score": "0.10083",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.032078",
                    "ticker_sentiment_score": "0.031324",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.064104",
                    "ticker_sentiment_score": "0.146467",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.032078",
                    "ticker_sentiment_score": "0.10083",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MORN",
                    "relevance_score": "0.048101",
                    "ticker_sentiment_score": "0.112638",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ACN",
                    "relevance_score": "0.032078",
                    "ticker_sentiment_score": "0.10083",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SAFRF",
                    "relevance_score": "0.016042",
                    "ticker_sentiment_score": "0.091909",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.048101",
                    "ticker_sentiment_score": "0.001994",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NSRGF",
                    "relevance_score": "0.016042",
                    "ticker_sentiment_score": "0.017574",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.096027",
                    "ticker_sentiment_score": "0.083384",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Want Decades of Passive Income? 2 Stocks to Buy Now.",
            "url": "https://www.fool.com/investing/2024/03/22/want-decades-of-passive-income-2-stocks-to-buy-now/",
            "time_published": "20240322T082500",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "There aren't many guarantees in the equity market, but the dividend payouts of Johnson & Johnson and Abbott Laboratories may be as close as it gets to a sure thing.",
            "banner_image": "https://media.ycharts.com/charts/f446e49093d77d67a17c38a637be54f2.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.26315,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ISRG",
                    "relevance_score": "0.047465",
                    "ticker_sentiment_score": "0.188654",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.448316",
                    "ticker_sentiment_score": "0.330782",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.448316",
                    "ticker_sentiment_score": "0.347852",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Johnson & Johnson's Abiomed Unit Recalls Instructions For Some Impella Blood Pumps Due To Cutting Risks - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/news/large-cap/24/03/37878539/johnson-johnsons-abiomed-unit-recalls-instructions-for-some-impella-blood-pumps-due-to-cutting-ris",
            "time_published": "20240321T183138",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "On Thursday, Johnson & Johnson's JNJ Abiomed said it is recalling its Impella Left Sided Blood Pumps because the pump catheter may perforate ( cut ) the wall of the left ventricle in the heart. During operations, the Impella device could cut through the wall of the left ventricle.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Impella-Pump-Photo-via-JNJ.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.083227,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.350564",
                    "ticker_sentiment_score": "0.266168",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "1 Magnificent Growth Stock to Buy and Hold",
            "url": "https://www.fool.com/investing/2024/03/21/1-magnificent-growth-stock-to-buy-and-hold/",
            "time_published": "20240321T124500",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "Investing in this company 10 years ago would have produced excellent returns, but it's not too late -- far from it.",
            "banner_image": "https://media.ycharts.com/charts/c61dc5c86256b5d93b6ae8dff7ca618f.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.171972,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MDT",
                    "relevance_score": "0.062597",
                    "ticker_sentiment_score": "0.036019",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ISRG",
                    "relevance_score": "0.567746",
                    "ticker_sentiment_score": "0.216088",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.124809",
                    "ticker_sentiment_score": "0.041961",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Bristol Myers  ( BMY )  Gets EC Nod for Abecma's Label Expansion",
            "url": "https://www.zacks.com/stock/news/2243958/bristol-myers-bmy-gets-ec-nod-for-abecmas-label-expansion",
            "time_published": "20240321T115300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Bristol Myers (BMY) wins European Commission's approval for the label expansion of its CAR T cell immunotherapy Abecma in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2106.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.917436"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.23117,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ADMA",
                    "relevance_score": "0.212674",
                    "ticker_sentiment_score": "0.191017",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ANIP",
                    "relevance_score": "0.212674",
                    "ticker_sentiment_score": "0.202264",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSVT",
                    "relevance_score": "0.128592",
                    "ticker_sentiment_score": "0.097714",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.04303",
                    "ticker_sentiment_score": "-0.062407",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.334008",
                    "ticker_sentiment_score": "0.187051",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.04303",
                    "ticker_sentiment_score": "-0.062407",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Should You Buy 3M Before April 1?",
            "url": "https://www.fool.com/investing/2024/03/21/should-you-buy-3m-before-april-1st/",
            "time_published": "20240321T090200",
            "authors": [
                "Matt DiLallo"
            ],
            "summary": "A looming stock spinoff should give investors a reason to pause.",
            "banner_image": "https://media.ycharts.com/charts/036e952319cf0965d91f9e1b90f7f6e3.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.998356"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.795202"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.242764,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.113062",
                    "ticker_sentiment_score": "0.059169",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.056674",
                    "ticker_sentiment_score": "0.004005",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NLOP",
                    "relevance_score": "0.056674",
                    "ticker_sentiment_score": "0.101109",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update",
            "url": "https://www.globenewswire.com/news-release/2024/03/20/2849779/0/en/Alvotech-Reports-Financial-Results-for-Full-Year-2023-and-Provides-a-Business-Update.html",
            "time_published": "20240320T201500",
            "authors": [
                "Alvotech"
            ],
            "summary": "Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2023 and provided a summary of recent pipeline and corporate highlights.",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.839681"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.955357"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.131766,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.011791",
                    "ticker_sentiment_score": "0.085539",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.011791",
                    "ticker_sentiment_score": "0.085539",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LTUS",
                    "relevance_score": "0.011791",
                    "ticker_sentiment_score": "0.053881",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.023579",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALVO",
                    "relevance_score": "0.342487",
                    "ticker_sentiment_score": "0.166948",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.011791",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TEVA",
                    "relevance_score": "0.011791",
                    "ticker_sentiment_score": "0.053881",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KMDA",
                    "relevance_score": "0.011791",
                    "ticker_sentiment_score": "0.053881",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.011791",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.011791",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:ISK",
                    "relevance_score": "0.035363",
                    "ticker_sentiment_score": "0.166852",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:SEK",
                    "relevance_score": "0.023579",
                    "ticker_sentiment_score": "0.137997",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.035363",
                    "ticker_sentiment_score": "0.215495",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update",
            "url": "https://www.globenewswire.com/news-release/2024/03/20/2849778/0/en/Alvotech-Reports-Financial-Results-for-Full-Year-2023-and-Provides-a-Business-Update.html",
            "time_published": "20240320T201500",
            "authors": [
                "Alvotech"
            ],
            "summary": "REYKJAVIK, Iceland, March 20, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2023 and provided a ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.839681"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.955357"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.129421,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.011762",
                    "ticker_sentiment_score": "0.085519",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.011762",
                    "ticker_sentiment_score": "0.085519",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LTUS",
                    "relevance_score": "0.011762",
                    "ticker_sentiment_score": "0.053868",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.023521",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALVO",
                    "relevance_score": "0.341699",
                    "ticker_sentiment_score": "0.166635",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.011762",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TEVA",
                    "relevance_score": "0.011762",
                    "ticker_sentiment_score": "0.053868",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KMDA",
                    "relevance_score": "0.011762",
                    "ticker_sentiment_score": "0.053868",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.011762",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.011762",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:ISK",
                    "relevance_score": "0.035276",
                    "ticker_sentiment_score": "0.164818",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:SEK",
                    "relevance_score": "0.023521",
                    "ticker_sentiment_score": "0.135974",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.035276",
                    "ticker_sentiment_score": "0.214421",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy - Johnson & Johnson  ( NYSE:JNJ ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
            "url": "https://www.benzinga.com/24/03/37850854/genscript-losses-shrink-on-strong-growth-for-cancer-cell-therapy",
            "time_published": "20240320T153012",
            "authors": [
                "The Bamboo Works"
            ],
            "summary": "GenScript's cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend's Carvykti is expected to hit annual production capacity of 10,000 doses by the end of 2025",
            "banner_image": "https://cdn.benzinga.com/files/genscript_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.918141"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.138772,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LEGN",
                    "relevance_score": "0.384397",
                    "ticker_sentiment_score": "0.190643",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WUXAY",
                    "relevance_score": "0.033375",
                    "ticker_sentiment_score": "0.074487",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.09989",
                    "ticker_sentiment_score": "0.03532",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GNNSF",
                    "relevance_score": "0.09989",
                    "ticker_sentiment_score": "0.077907",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.066691",
                    "ticker_sentiment_score": "-0.119272",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Migraine Drugs Market Continues To Surge At A Rate Of More Than 6%, Fueled By Innovation And Demand As Per The Business Research Company's Migraine Drugs Global Market Report 2024",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37850847/migraine-drugs-market-continues-to-surge-at-a-rate-of-more-than-6-fueled-by-innovation-and-demand-",
            "time_published": "20240320T153000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LONDON, March 20, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Migraine Drugs Global Market Report 2024, the migraine drugs market has experienced robust growth in recent years, with promising projections for the future.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.351945,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BAYZF",
                    "relevance_score": "0.053153",
                    "ticker_sentiment_score": "0.256846",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.053153",
                    "ticker_sentiment_score": "0.256846",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.053153",
                    "ticker_sentiment_score": "0.256846",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Interstitial Cystitis Drugs Market Witnesses Robust Growth, Predicted To Surge At A Rate Of More Than 5% Through 2024-2028 As Per The Business Research Company's Interstitial Cystitis Drugs Global Market Report 2024",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37850849/interstitial-cystitis-drugs-market-witnesses-robust-growth-predicted-to-surge-at-a-rate-of-more-th",
            "time_published": "20240320T153000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LONDON, March 20, 2024 ( GLOBE NEWSWIRE ) -- The Business Research Company's Interstitial Cystitis Drugs Global Market Report 2024, the interstitial cystitis drugs market has experienced significant growth in recent years, with notable projections indicating continued expansion.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.412328,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PFE",
                    "relevance_score": "0.05257",
                    "ticker_sentiment_score": "0.14497",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.05257",
                    "ticker_sentiment_score": "0.14497",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Jim Cramer Reveals Nvidia's Non-Tech Partners That Can Be Potential Market Winner: 'Best Opportunities' - Getty Images Holdings  ( NYSE:GETY ) , GE HealthCare Techs  ( NASDAQ:GEHC ) ",
            "url": "https://www.benzinga.com/markets/equities/24/03/37838206/jim-cramer-reveals-nvidias-non-tech-partners-that-can-be-potential-market-winner-best-opportunit",
            "time_published": "20240320T030350",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "CNBC host Jim Cramer has spotlighted several lesser-known partners of NVIDIA Corp NVDA that could potentially benefit from the company's advanced artificial intelligence ( AI ) technology.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/jim-cramer-nvidia-shutter_6.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.274768,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GEHC",
                    "relevance_score": "0.181137",
                    "ticker_sentiment_score": "0.218314",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.507932",
                    "ticker_sentiment_score": "0.261207",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SSTK",
                    "relevance_score": "0.181137",
                    "ticker_sentiment_score": "0.145654",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GETY",
                    "relevance_score": "0.181137",
                    "ticker_sentiment_score": "0.145654",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.091162",
                    "ticker_sentiment_score": "0.158334",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.181137",
                    "ticker_sentiment_score": "0.218314",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37829815/us-retinal-specialists-highlight-the-greatest-opportunity-for-gene-therapies",
            "time_published": "20240319T182000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "EXTON, PA, March 19, 2024 ( GLOBE NEWSWIRE ) -- Gene therapies have emerged as a ray of hope, particularly in the realm of eye diseases. The focus on the eye has provided researchers with a promising pathway for delivering genetic material with precision and safety.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.278804,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ADVM",
                    "relevance_score": "0.054114",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.054114",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.054114",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Cartilage Repair Market Anticipates Rapid Growth, Projected To Reach $2.3 Billion In 2028 As Per The Business Research Company's Cartilage Repair Global Market Report 2024",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37826138/cartilage-repair-market-anticipates-rapid-growth-projected-to-reach-2-3-billion-in-2028-as-per-the",
            "time_published": "20240319T154000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LONDON, March 19, 2024 ( GLOBE NEWSWIRE ) -- The Business Research Company's Cartilage Repair Market Global Report 2024 forecasts significant growth, with the cartilage repair market size expected to rise from $1.24 billion in 2023 to $1.42 billion in 2024, demonstrating a compound annual growth ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.289805,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MDT",
                    "relevance_score": "0.056407",
                    "ticker_sentiment_score": "0.10634",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SYK",
                    "relevance_score": "0.056407",
                    "ticker_sentiment_score": "0.10634",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BVS",
                    "relevance_score": "0.112532",
                    "ticker_sentiment_score": "0.235268",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.056407",
                    "ticker_sentiment_score": "0.10634",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson  ( JNJ ) , Nvidia Unite to Boost AI for Surgery",
            "url": "https://www.zacks.com/stock/news/2242895/johnson-johnson-jnj-nvidia-unite-to-boost-ai-for-surgery",
            "time_published": "20240319T145100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Johnson & Johnson (JNJ) collaborates with Nvidia to facilitate the creation of AI-based models and the deployment of applications, offering a route to scale within its digital ecosystem for surgery.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.2024,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.189175",
                    "ticker_sentiment_score": "0.142341",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAH",
                    "relevance_score": "0.250386",
                    "ticker_sentiment_score": "0.12185",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.189175",
                    "ticker_sentiment_score": "0.139372",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COR",
                    "relevance_score": "0.189175",
                    "ticker_sentiment_score": "0.100745",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.527295",
                    "ticker_sentiment_score": "0.326956",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
            "url": "https://www.zacks.com/stock/news/2242578/should-you-invest-in-the-vanguard-health-care-etf-vht",
            "time_published": "20240319T102005",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sector ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default75.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.250395,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.135347",
                    "ticker_sentiment_score": "0.064508",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.067919",
                    "ticker_sentiment_score": "0.125823",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.135347",
                    "ticker_sentiment_score": "0.064508",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.135347",
                    "ticker_sentiment_score": "0.064508",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Nvidia CEO Jensen Huang unveils successor to its all-conquering AI chip",
            "url": "https://www.business-standard.com/world-news/nvidia-ceo-jensen-huang-unveils-successor-to-its-all-conquering-ai-chip-124031900079_1.html",
            "time_published": "20240319T031146",
            "authors": [
                "Bloomberg"
            ],
            "summary": "A new processor design called Blackwell is multiple times faster at handling the models that underpin AI, the company said at its GTC conference in San Jose, California. That includes the process of developing the technology - a stage known as training - and the running of it, which is called ...",
            "banner_image": "https://bsmedia.business-standard.com/_media/bs/img/article/2024-03/19/full/1710817667-6636.png?im=Resize=(640,480)",
            "source": "Business Standard",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.business-standard.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.20136,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.126339",
                    "ticker_sentiment_score": "0.107449",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.084423",
                    "ticker_sentiment_score": "0.078232",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.042271",
                    "ticker_sentiment_score": "0.120842",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.366661",
                    "ticker_sentiment_score": "0.230151",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.042271",
                    "ticker_sentiment_score": "0.136212",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMAWF",
                    "relevance_score": "0.042271",
                    "ticker_sentiment_score": "0.108929",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BYDDF",
                    "relevance_score": "0.042271",
                    "ticker_sentiment_score": "0.108929",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.042271",
                    "ticker_sentiment_score": "0.108929",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ORCL",
                    "relevance_score": "0.042271",
                    "ticker_sentiment_score": "0.035889",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WSFL",
                    "relevance_score": "0.042271",
                    "ticker_sentiment_score": "0.108929",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSM",
                    "relevance_score": "0.042271",
                    "ticker_sentiment_score": "0.033941",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson  ( JNJ )  Stock Dips While Market Gains: Key Facts",
            "url": "https://www.zacks.com/stock/news/2242442/johnson-johnson-jnj-stock-dips-while-market-gains-key-facts",
            "time_published": "20240318T214520",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Johnson & Johnson (JNJ) closed the most recent trading day at $156.76, moving -0.9% from the previous trading session.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default241.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.983783"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.235283,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.56415",
                    "ticker_sentiment_score": "0.324595",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why Is 2seventy bio Stock Trading Higher On Monday? - Legend Biotech  ( NASDAQ:LEGN ) , Johnson & Johnson  ( NYSE:JNJ ) , 2seventy bio  ( NASDAQ:TSVT ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37785358/fda-adcomm-favors-expanded-use-of-johnson-johnson-bristol-myers-car-t-therapies-for-type-of-blood",
            "time_published": "20240318T141636",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Friday, the FDA's Oncologic Drugs Advisory Committee ( ODAC ) voted positively ( 8-3 ) favoring expanded use of Bristol Myers Squibb & Co BMY 2seventy bio Inc's TSVT Abecma ( idecabtagene vicleucel ) .",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Cancer-Image-by-PDPics-from-Pixabay-_7.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.283561,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "TSVT",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.274691",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LEGN",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.131011",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.274691",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.131011",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Bristol Myers'  ( BMY )  Abecma Gets ODAC Votes for Label Expansion",
            "url": "https://www.zacks.com/stock/news/2242244/bristol-myers-bmy-abecma-gets-odac-votes-for-label-expansion",
            "time_published": "20240318T133100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2106.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.150204,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ADMA",
                    "relevance_score": "0.132368",
                    "ticker_sentiment_score": "0.142339",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSVT",
                    "relevance_score": "0.175859",
                    "ticker_sentiment_score": "0.058482",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.044304",
                    "ticker_sentiment_score": "-0.055744",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.302642",
                    "ticker_sentiment_score": "0.11131",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.132368",
                    "ticker_sentiment_score": "-0.083335",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson  ( JNJ )  is Attracting Investor Attention: Here is What You Should Know",
            "url": "https://www.zacks.com/stock/news/2241983/johnson-johnson-jnj-is-attracting-investor-attention-here-is-what-you-should-know",
            "time_published": "20240318T130016",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default261.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.54554"
                }
            ],
            "overall_sentiment_score": 0.215468,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.479385",
                    "ticker_sentiment_score": "0.142699",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Major shareholder announcement - BlackRock, Inc.",
            "url": "https://www.globenewswire.com/news-release/2024/03/18/2847710/0/en/Major-shareholder-announcement-BlackRock-Inc.html",
            "time_published": "20240318T113200",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.142267,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.646507",
                    "ticker_sentiment_score": "0.295339",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.24289",
                    "ticker_sentiment_score": "0.073834",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.24289",
                    "ticker_sentiment_score": "0.073834",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.24289",
                    "ticker_sentiment_score": "0.073834",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Major shareholder announcement - AIM International Mutual Funds",
            "url": "https://www.globenewswire.com/news-release/2024/03/18/2847693/0/en/Major-shareholder-announcement-AIM-International-Mutual-Funds.html",
            "time_published": "20240318T112800",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.152916,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.499789",
                    "ticker_sentiment_score": "0.294618",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.079018",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.079018",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.079018",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Major shareholder announcement - Invesco Ltd.",
            "url": "https://www.globenewswire.com/news-release/2024/03/18/2847688/0/en/Major-shareholder-announcement-Invesco-Ltd.html",
            "time_published": "20240318T112500",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.088322,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.546745",
                    "ticker_sentiment_score": "0.155332",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.29234",
                    "ticker_sentiment_score": "0.08587",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.29234",
                    "ticker_sentiment_score": "0.08587",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.29234",
                    "ticker_sentiment_score": "0.08587",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer - Clearside Biomedical  ( NASDAQ:CLSD ) ",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37776311/clearside-biomedical-appoints-victor-chong-m-d-mba-as-chief-medical-officer",
            "time_published": "20240318T110500",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "ALPHARETTA, Ga., March 18, 2024 ( GLOBE NEWSWIRE ) -- Clearside Biomedical, Inc. CLSD, a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space ( SCS® ) , announced today that Victor Chong, M.D., MBA was appointed Chief Medical ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.137807,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CLSD",
                    "relevance_score": "0.107335",
                    "ticker_sentiment_score": "0.097075",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.035875",
                    "ticker_sentiment_score": "0.051615",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "J&J  ( JNJ )  Gets FDA Panel Vote for Carvykti's Expanded Use",
            "url": "https://www.zacks.com/stock/news/2241906/jj-jnj-gets-fda-panel-vote-for-carvyktis-expanded-use",
            "time_published": "20240318T105500",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "J&J (JNJ) is looking for expansion of Carvykti's label for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.9545"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.222324,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ADMA",
                    "relevance_score": "0.433523",
                    "ticker_sentiment_score": "0.316778",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VNDA",
                    "relevance_score": "0.367141",
                    "ticker_sentiment_score": "0.103616",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.367141",
                    "ticker_sentiment_score": "0.285716",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.297661",
                    "ticker_sentiment_score": "0.116829",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "India Baby Care Products Market size to grow by USD 15.69 billion from 2022 to 2027, Market is fragmented due to the ... - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/india-baby-care-products-market-size-to-grow-by-usd-15-69-billion-from-2022-to-2027--market-is-fragmented-due-to-the-presence-of-prominent-companies-like-abbott-laboratories-artsana-spa-bio-veda-action-research-co-and-many-mor-302090314.html",
            "time_published": "20240318T011200",
            "authors": [],
            "summary": "India Baby Care Products Market size to grow by USD 15.69 billion from 2022 to 2027, Market is fragmented due to the ... PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.260822,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KMB",
                    "relevance_score": "0.033751",
                    "ticker_sentiment_score": "0.064873",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MHCRF",
                    "relevance_score": "0.033751",
                    "ticker_sentiment_score": "0.064873",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.033751",
                    "ticker_sentiment_score": "0.064873",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PIGEF",
                    "relevance_score": "0.033751",
                    "ticker_sentiment_score": "0.064873",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.033751",
                    "ticker_sentiment_score": "0.064873",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.033751",
                    "ticker_sentiment_score": "0.064873",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UL",
                    "relevance_score": "0.033751",
                    "ticker_sentiment_score": "0.064873",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PHG",
                    "relevance_score": "0.033751",
                    "ticker_sentiment_score": "0.064873",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Investing $10,000 in Each of These 3 Vanguard ETFs Could Generate $1,164 per Year in Passive Income",
            "url": "https://www.fool.com/investing/2024/03/17/investing-vanguard-etf-passive-income/",
            "time_published": "20240317T113000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "These funds provide investors with an easy way to rake in passive income.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769275/man-with-arms-behind-head-looking-at-laptop.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.191945,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.135921",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.135921",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PG",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.135921",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.135921",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMT",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.102902",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CCI",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.102902",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLD",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.102902",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BHP",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.165946",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "EQIX",
                    "relevance_score": "0.056143",
                    "ticker_sentiment_score": "0.102902",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Market Cap Game Show: Matt Argersinger vs. Bill Mann",
            "url": "https://www.fool.com/investing/2024/03/16/market-cap-game-show-matt-argersinger-vs-bill-mann/",
            "time_published": "20240316T130000",
            "authors": [
                "Motley Fool Staff"
            ],
            "summary": "Test your knowledge of companies' value on the stock market.",
            "banner_image": "https://g.foolcdn.com/editorial/images/769276/image.jpeg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.682689"
                }
            ],
            "overall_sentiment_score": 0.195314,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.008026",
                    "ticker_sentiment_score": "0.05881",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.004013",
                    "ticker_sentiment_score": "0.087925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KLG",
                    "relevance_score": "0.024073",
                    "ticker_sentiment_score": "0.031939",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAH",
                    "relevance_score": "0.004013",
                    "ticker_sentiment_score": "0.09207",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GLP",
                    "relevance_score": "0.004013",
                    "ticker_sentiment_score": "-0.076975",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABNB",
                    "relevance_score": "0.01605",
                    "ticker_sentiment_score": "0.038098",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "K",
                    "relevance_score": "0.032094",
                    "ticker_sentiment_score": "0.060982",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAL",
                    "relevance_score": "0.004013",
                    "ticker_sentiment_score": "0.191735",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CCL",
                    "relevance_score": "0.01605",
                    "ticker_sentiment_score": "0.058104",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMGTF",
                    "relevance_score": "0.004013",
                    "ticker_sentiment_score": "0.191735",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AVD",
                    "relevance_score": "0.012038",
                    "ticker_sentiment_score": "0.054549",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRC",
                    "relevance_score": "0.064136",
                    "ticker_sentiment_score": "0.081082",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.004013",
                    "ticker_sentiment_score": "0.124721",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EBAY",
                    "relevance_score": "0.044119",
                    "ticker_sentiment_score": "0.05532",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ETSY",
                    "relevance_score": "0.032094",
                    "ticker_sentiment_score": "0.022631",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BBW",
                    "relevance_score": "0.044119",
                    "ticker_sentiment_score": "0.096211",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KMX",
                    "relevance_score": "0.012038",
                    "ticker_sentiment_score": "0.043103",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.008026",
                    "ticker_sentiment_score": "0.08488",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MIDD",
                    "relevance_score": "0.028084",
                    "ticker_sentiment_score": "0.046541",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRNC",
                    "relevance_score": "0.036103",
                    "ticker_sentiment_score": "0.053749",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.004013",
                    "ticker_sentiment_score": "0.191735",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Johnson & Johnson Stock Is Great. Here's Why You Shouldn't Buy It.",
            "url": "https://www.fool.com/investing/2024/03/16/johnson-johnson-great-why-shouldnt-buy-stock/",
            "time_published": "20240316T075500",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Johnson & Johnson's days of being a top healthcare stock could be long gone.",
            "banner_image": "https://g.foolcdn.com/editorial/images/768803/concerned-person-looking-at-a-tablet.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.100506,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.114956",
                    "ticker_sentiment_score": "0.018839",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.484697",
                    "ticker_sentiment_score": "0.064236",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Abbott's Formula Selloff Could Be A Buying Opportunity, Says Analyst",
            "url": "https://www.investors.com/news/technology/abbott-stock-infant-formula-similac-lawsuits/",
            "time_published": "20240315T163313",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Abbott Stock Dives As Fellow Formula Maker Fined $60 Million Following Infant Death Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-Abbott-05-shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.977154"
                }
            ],
            "overall_sentiment_score": -0.096686,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ABT",
                    "relevance_score": "0.166169",
                    "ticker_sentiment_score": "-0.029786",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ISRG",
                    "relevance_score": "0.083541",
                    "ticker_sentiment_score": "-0.026914",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.166169",
                    "ticker_sentiment_score": "-0.06886",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.166169",
                    "ticker_sentiment_score": "-0.06886",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RBGPF",
                    "relevance_score": "0.246999",
                    "ticker_sentiment_score": "-0.305291",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Monoclonal Antibody  ( mABs )  Therapeutics Market Worth $497.5 billion | MarketsandMarkets™",
            "url": "https://www.prnewswire.com/news-releases/monoclonal-antibody-mabs-therapeutics-market-worth-497-5-billion--marketsandmarkets-302090362.html",
            "time_published": "20240315T143000",
            "authors": [
                "MarketsandMarkets"
            ],
            "summary": "CHICAGO, March 15, 2024 /PRNewswire/ -- Monoclonal Antibody ( mABs ) Therapeutics Market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by ...",
            "banner_image": "https://mma.prnewswire.com/media/2297424/MarketsandMarkets_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.227469,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.024372",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "0.078722",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.073024",
                    "ticker_sentiment_score": "0.08487",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "0.078722",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "0.078722",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "0.064394",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "0.078722",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "0.078722",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.024372",
                    "ticker_sentiment_score": "0.081181",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "0.078722",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "0.078722",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TAK",
                    "relevance_score": "0.04872",
                    "ticker_sentiment_score": "0.078722",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More",
            "url": "https://www.zacks.com/stock/news/2241296/pharma-stock-roundup-azns-new-acquisition-fda-updates-for-nvo-lly-and-more",
            "time_published": "20240315T131900",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.200599,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.085173",
                    "ticker_sentiment_score": "0.06412",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.169378",
                    "ticker_sentiment_score": "0.118514",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.127456",
                    "ticker_sentiment_score": "0.105455",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.210823",
                    "ticker_sentiment_score": "0.128918",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.085173",
                    "ticker_sentiment_score": "0.083978",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Bristol Myers  ( BMY )  Gets FDA Nod for Breyanzi's Label Expansion",
            "url": "https://www.zacks.com/stock/news/2241446/bristol-myers-bmy-gets-fda-nod-for-breyanzis-label-expansion",
            "time_published": "20240315T131400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.858979"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.099238,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ADMA",
                    "relevance_score": "0.230454",
                    "ticker_sentiment_score": "0.174228",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSVT",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "-0.074888",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.139534",
                    "ticker_sentiment_score": "0.063123",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.274834",
                    "ticker_sentiment_score": "0.186681",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.139534",
                    "ticker_sentiment_score": "-0.097325",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus - AstraZeneca  ( NASDAQ:AZN ) , Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37716166/congressional-scrutiny-intensifies-on-chinese-biotech-firms-wuxi-apptec-faces-biotech-exodus",
            "time_published": "20240314T200301",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Amid the ongoing scrutiny from Congress, WuXi AppTec and its affiliates face another setback as the Biotechnology Innovation Organization ( BIO ) , a U.S. industry lobbying group, severs ties with the Chinese biotech.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/US-China-Tatiana-Popova-and-rawf8-by-Shu.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": -0.065123,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.259267",
                    "ticker_sentiment_score": "0.106372",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WXXWY",
                    "relevance_score": "0.174587",
                    "ticker_sentiment_score": "-0.033926",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WUXAY",
                    "relevance_score": "0.340915",
                    "ticker_sentiment_score": "-0.06817",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.174587",
                    "ticker_sentiment_score": "0.069834",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.174587",
                    "ticker_sentiment_score": "0.069834",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.174587",
                    "ticker_sentiment_score": "0.083857",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits - Bayer  ( OTC:BAYRY ) , Bayer  ( OTC:BAYZF ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37716027/german-conglomerate-bayer-goes-johnson-johnson-way-to-tackle-its-cancer-related-lawsuits",
            "time_published": "20240314T195901",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Bayer AG BAYRY BAYZF is reportedly considering utilizing the Texas Two-Step bankruptcy approach to tackle the onslaught of lawsuits in the United States implicating its Roundup weedkiller causing cancer.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Bayer-AG-Cross-2005_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.095837,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MMM",
                    "relevance_score": "0.224903",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAYZF",
                    "relevance_score": "0.224903",
                    "ticker_sentiment_score": "-0.435121",
                    "ticker_sentiment_label": "Bearish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.224903",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights UnitedHealth Johnson & Johnson, Oracle, Wells Fargo & Co and Caterpillar.",
            "url": "https://www.zacks.com/stock/news/2240459/the-zacks-analyst-blog-highlights-unitedhealth-johnson-johnson-oracle-wells-fargo-co-and-caterpillar",
            "time_published": "20240314T120000",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "UnitedHealth, Johnson & Johnson, Oracle, Wells Fargo & Co and Caterpillar are the part of the Zacks top Analyst Blog .",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/79/525.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.297516,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ORCL",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.192808",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.133841",
                    "ticker_sentiment_score": "0.037938",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.289426",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.133841",
                    "ticker_sentiment_score": "0.037938",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.199584",
                    "ticker_sentiment_score": "0.049258",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update",
            "url": "https://www.globenewswire.com/news-release/2024/03/14/2846139/0/en/AC-Immune-Reports-Full-Year-2023-Financial-Results-and-Provides-a-Corporate-Update.html",
            "time_published": "20240314T110000",
            "authors": [
                "AC Immune SA"
            ],
            "summary": "AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update • ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2 • ACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease on track for interim data in H2 • Cash of CHF 103 million at year end, ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/0065cdfd-b9fc-4994-8aca-731c1d031b51",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.614606"
                }
            ],
            "overall_sentiment_score": 0.130867,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ACIU",
                    "relevance_score": "0.265934",
                    "ticker_sentiment_score": "0.102851",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSSMY",
                    "relevance_score": "0.020848",
                    "ticker_sentiment_score": "0.03387",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.041682",
                    "ticker_sentiment_score": "0.048052",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Cellulite Treatment Market Projected to Expand at a CAGR of 10.2%, Elevating to a Valuation of USD 1.7 billion by 2031: Transparency Market Research, Inc.",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37689561/cellulite-treatment-market-projected-to-expand-at-a-cagr-of-10-2-elevating-to-a-valuation-of-usd-1",
            "time_published": "20240314T094800",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "Wilmington, Delaware, United States, March 14, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The cellulite treatment market was worth US$ 710.8 million in 2022. By the end of 2031, it is estimated to reach US$ 1.7 billion, increasing at a CAGR of 10.2% during the forecast period.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.302615,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.036643",
                    "ticker_sentiment_score": "0.053336",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMGTF",
                    "relevance_score": "0.109622",
                    "ticker_sentiment_score": "0.105134",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CUTR",
                    "relevance_score": "0.073209",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.036643",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers - Johnson & Johnson  ( NYSE:JNJ ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37671173/fda-to-review-two-cell-therapies-for-multiple-myeloma-this-week-johnson-johnson-and-bristol-myers",
            "time_published": "20240313T174359",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "On Friday, 15 March, the FDA's Oncologic Drugs Advisory Committee will meet to discuss Johnson & Johnson JNJ / Legend Biotech Corporation's LEGN supplemental biologics license application for Carvykti ( ciltacabtagene autoleucel ) for relapsed or refractory multiple myeloma, who have received at ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Cancer-Image-by-PDPics-from-Pixabay-_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.141877,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BMY",
                    "relevance_score": "0.205807",
                    "ticker_sentiment_score": "-0.056764",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.304428",
                    "ticker_sentiment_score": "0.13617",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LEGN",
                    "relevance_score": "0.398148",
                    "ticker_sentiment_score": "0.140611",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Chronic Myeloid Leukemia Treatment Market On A Growth Trajectory: Market Size To Reach $12 Billion By 2028 As Per The Business Research Company's Chronic Myeloid Leukemia Treatment Global Market Report 2024",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37665480/chronic-myeloid-leukemia-treatment-market-on-a-growth-trajectory-market-size-to-reach-12-billion-b",
            "time_published": "20240313T153000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "LONDON, March 13, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Chronic Myeloid Leukemia Treatment Global Market Report 2024, the chronic myeloid leukemia treatment market has witnessed robust growth in recent years, and projections indicate a continued upward trajectory.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.246224,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "PRPO",
                    "relevance_score": "0.057079",
                    "ticker_sentiment_score": "0.244371",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.113866",
                    "ticker_sentiment_score": "0.228771",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.057079",
                    "ticker_sentiment_score": "0.157495",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Healthy Returns: What's next in the legal fight over Medicare drug price negotiations",
            "url": "https://www.cnbc.com/2024/03/13/healthy-returns-whats-next-in-medicare-drug-price-negotiations.html",
            "time_published": "20240313T134315",
            "authors": [
                "Annika Kim Constantino",
                "Ashley Capoot"
            ],
            "summary": "The legal battle over Medicare drug price negotiations is so far looking favorable for the Biden administration. Meanwhile, CNBC is on the ground at HIMSS!",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107130655-1665090556176-gettyimages-1431082899-_m021740_4b5641b7-17d1-48f7-8db3-6aef2e513b99.jpeg?v=1710336586&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.10078,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.068698",
                    "ticker_sentiment_score": "0.113653",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.034381",
                    "ticker_sentiment_score": "0.033826",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.034381",
                    "ticker_sentiment_score": "-0.112074",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.034381",
                    "ticker_sentiment_score": "0.083469",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Nanotechnology's Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX's Nanotechnology - AstraZeneca  ( NASDAQ:AZN ) , FendX Technologies  ( OTC:FDXTF ) ",
            "url": "https://www.benzinga.com/partner/biotech/24/03/37655895/nanotechnologys-promising-role-in-fighting-infectious-diseases-protecting-surfaces-with-fendxs-na",
            "time_published": "20240313T121807",
            "authors": [
                "Meg Flippin"
            ],
            "summary": "From therapeutics to new drug delivery systems, nanotechnology can play an important role in fighting infectious diseases. A prime example is evident in the development of the COVID-19 vaccines. During the pandemic, Pfizer Inc. PFE, Moderna Inc. MRNA, Johnson & Johnson JNJ, AstraZeneca Plc.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Screenshot-2024-03-13-at-5-45-52-PM.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.495866"
                }
            ],
            "overall_sentiment_score": 0.084406,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SHTDF",
                    "relevance_score": "0.04406",
                    "ticker_sentiment_score": "0.147254",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.087985",
                    "ticker_sentiment_score": "0.155556",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.087985",
                    "ticker_sentiment_score": "0.155556",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FDXTF",
                    "relevance_score": "0.087985",
                    "ticker_sentiment_score": "0.020078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.087985",
                    "ticker_sentiment_score": "0.155556",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.087985",
                    "ticker_sentiment_score": "0.155556",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "FOOT LOCKER, INC. NAMES CINDY CARLISLE CHIEF HUMAN RESOURCES OFFICER",
            "url": "https://www.newswire.ca/news-releases/foot-locker-inc-names-cindy-carlisle-chief-human-resources-officer-826430832.html",
            "time_published": "20240313T120000",
            "authors": [
                "Foot Locker",
                "Inc."
            ],
            "summary": "Carlisle brings over 24 years of leadership experience to her role at Foot Locker, Inc. NEW YORK, March 13, 2024 /CNW/ -- Foot Locker, Inc. ( NYSE: FL ) today announced that Cindy Carlisle has assumed the role of Executive Vice President and Chief Human Resources Officer.",
            "banner_image": "https://mma.prnewswire.com/media/2360986/Foot_Locker_Inc_Logo_Black_Logo.jpg?p=facebook",
            "source": "Canada Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.newswire.ca",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.31615,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SYK",
                    "relevance_score": "0.114682",
                    "ticker_sentiment_score": "-0.123508",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FL",
                    "relevance_score": "0.916507",
                    "ticker_sentiment_score": "0.523913",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.114682",
                    "ticker_sentiment_score": "-0.123508",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 No-Brainer Stocks to Buy With $300 Right Now",
            "url": "https://www.fool.com/investing/2024/03/13/3-no-brainer-stocks-to-buy-with-300-right-now/",
            "time_published": "20240313T092100",
            "authors": [
                "Sean Williams"
            ],
            "summary": "A reasonably modest amount of money can go a long way when it's put to work in historically cheap, industry-leading businesses.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F768988%2Fthree-one-hundred-dollar-bills-cash-money-buried-sand-sunset-beach-summer-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99977"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.769861"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.179662,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BABA",
                    "relevance_score": "0.171485",
                    "ticker_sentiment_score": "0.075291",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.028798",
                    "ticker_sentiment_score": "0.134087",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.086245",
                    "ticker_sentiment_score": "0.290282",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.143244",
                    "ticker_sentiment_score": "0.186976",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Appointment of new CEO",
            "url": "https://www.globenewswire.com/news-release/2024/03/13/2845202/0/en/Appointment-of-new-CEO.html",
            "time_published": "20240313T083000",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. 255 ( Changed category - Inside information ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.170644,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.047736",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.047736",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.047736",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Appointment of new CEO",
            "url": "https://www.globenewswire.com/news-release/2024/03/13/2845193/0/en/Appointment-of-new-CEO.html",
            "time_published": "20240313T080200",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.170644,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AZN",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.047736",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.047736",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.128822",
                    "ticker_sentiment_score": "0.047736",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Faron's Financial Statement Release January 1 to December 31, 2023",
            "url": "https://www.globenewswire.com/news-release/2024/03/13/2845159/0/en/Faron-s-Financial-Statement-Release-January-1-to-December-31-2023.html",
            "time_published": "20240313T070000",
            "authors": [
                "Faron Pharmaceuticals Oy"
            ],
            "summary": "TURKU, Finland and BOSTON, March 13, 2024 ( GLOBE NEWSWIRE ) -- Faron Pharmaceuticals Ltd. ( \"Faron\" or \"the Company\" ) ( AIM: FARN, First North: FARON ) , a clinical-stage biopharmaceutical company focused on tackling cancers via novel myeloid cell targeted immunotherapies, today announced ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/ae344e9a-bc8e-4213-833f-0c0c97b7d047",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                }
            ],
            "overall_sentiment_score": 0.238637,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "OPTGF",
                    "relevance_score": "0.006375",
                    "ticker_sentiment_score": "0.073925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.006375",
                    "ticker_sentiment_score": "0.052082",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.006375",
                    "ticker_sentiment_score": "0.052082",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Golden Cross Alert: Johnson & Johnson Shines With Ambrx Deal, Bullish Technical Signal - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/general/biotech/24/03/37631893/golden-cross-alert-johnson-johnson-shines-with-ambrx-deal-bullish-technical-signal",
            "time_published": "20240312T190501",
            "authors": [
                "Surbhi Jain"
            ],
            "summary": "Johnson & Johnson JNJ stock hasn't displayed much momentum: it is down 1.22% over the past six months, up 5.57% over the past year and up 3% YTD. The stock recently made a Golden Cross on the charts, signaling a reversal in trend. Johnson & Johnson's recent acquisition of Ambrx Biopharma boosted ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2024/JohnsonampJohnson-Shutterstock.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.217661,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "AMAM",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.104876",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.617765",
                    "ticker_sentiment_score": "0.240641",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "CIO Leadership: The Call for Visionary Global Leadership Will Power the Discussion at HMG Strategy's 17th Annual New York CIO Summit of America on April 11",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37627110/cio-leadership-the-call-for-visionary-global-leadership-will-power-the-discussion-at-hmg-strategys",
            "time_published": "20240312T162332",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "WESTPORT, Conn., March 12, 2024 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 platform for enabling technology executives to reimagine the enterprise and reshape the business world, is thrilled to announce that its signature event - the 17th Annual New York CIO Summit of America - will be ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.214992,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CHH",
                    "relevance_score": "0.018257",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.018257",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UPWK",
                    "relevance_score": "0.018257",
                    "ticker_sentiment_score": "0.044744",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RNG",
                    "relevance_score": "0.054732",
                    "ticker_sentiment_score": "0.04905",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DRKTF",
                    "relevance_score": "0.054732",
                    "ticker_sentiment_score": "0.04905",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RMNI",
                    "relevance_score": "0.054732",
                    "ticker_sentiment_score": "0.04905",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UTZ",
                    "relevance_score": "0.018257",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBGSF",
                    "relevance_score": "0.036504",
                    "ticker_sentiment_score": "0.044163",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KFY",
                    "relevance_score": "0.018257",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PANW",
                    "relevance_score": "0.109206",
                    "ticker_sentiment_score": "0.055648",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CL",
                    "relevance_score": "0.018257",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PSN",
                    "relevance_score": "0.018257",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCO",
                    "relevance_score": "0.018257",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMG",
                    "relevance_score": "0.018257",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FUTU",
                    "relevance_score": "0.018257",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "APPN",
                    "relevance_score": "0.036504",
                    "ticker_sentiment_score": "0.050258",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NTNX",
                    "relevance_score": "0.054732",
                    "ticker_sentiment_score": "0.04905",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BACHY",
                    "relevance_score": "0.018257",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FTNT",
                    "relevance_score": "0.018257",
                    "ticker_sentiment_score": "0.044744",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALC",
                    "relevance_score": "0.018257",
                    "ticker_sentiment_score": "0.157071",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ZS",
                    "relevance_score": "0.054732",
                    "ticker_sentiment_score": "0.04905",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FUJIF",
                    "relevance_score": "0.018257",
                    "ticker_sentiment_score": "0.225042",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UPBD",
                    "relevance_score": "0.036504",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IDCBY",
                    "relevance_score": "0.018257",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BHE",
                    "relevance_score": "0.018257",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Global Contraceptive Drugs Market Size is Projected to Reach USD 28.96 billion by 2030, Growing at a CAGR of 7.3%: Straits Research - Agile Therapeutics  ( NASDAQ:AGRX ) , GSK  ( NYSE:GSK ) ",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37621870/global-contraceptive-drugs-market-size-is-projected-to-reach-usd-28-96-billion-by-2030-growing-at-",
            "time_published": "20240312T142000",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "New York, United States, March 12, 2024 ( GLOBE NEWSWIRE ) -- Contraception encompasses the use of drugs to prevent pregnancy, the transmission of sexually transmitted diseases ( STDs ) , the transmission of sexually transmitted infections ( STIs ) , family planning, and birth control.",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.174997,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "META",
                    "relevance_score": "0.03399",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AGRX",
                    "relevance_score": "0.135347",
                    "ticker_sentiment_score": "0.05971",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BAYZF",
                    "relevance_score": "0.03399",
                    "ticker_sentiment_score": "0.043225",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.03399",
                    "ticker_sentiment_score": "0.043225",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVS",
                    "relevance_score": "0.03399",
                    "ticker_sentiment_score": "0.043225",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TEVA",
                    "relevance_score": "0.03399",
                    "ticker_sentiment_score": "0.043225",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GSK",
                    "relevance_score": "0.101725",
                    "ticker_sentiment_score": "0.085346",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.101725",
                    "ticker_sentiment_score": "0.077847",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.03399",
                    "ticker_sentiment_score": "0.043225",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Here's Why You Should Retain Medtronic  ( MDT )  Stock for Now",
            "url": "https://www.zacks.com/stock/news/2239072/heres-why-you-should-retain-medtronic-mdt-stock-for-now",
            "time_published": "20240312T120300",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Investors continue to be optimistic about Medtronic (MDT) on the strength of the Neurosurgery and Cardiovascular and Neurosurgery portfolios.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.997845"
                }
            ],
            "overall_sentiment_score": 0.319885,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CAH",
                    "relevance_score": "0.158781",
                    "ticker_sentiment_score": "0.148603",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.2741",
                    "ticker_sentiment_score": "0.335866",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SYK",
                    "relevance_score": "0.158781",
                    "ticker_sentiment_score": "0.103728",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.039944",
                    "ticker_sentiment_score": "0.095015",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVA",
                    "relevance_score": "0.158781",
                    "ticker_sentiment_score": "0.090542",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.039944",
                    "ticker_sentiment_score": "0.095015",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "2 High-Yield Dow Jones Dividend Stocks to Buy Now and Hold Forever",
            "url": "https://www.fool.com/investing/2024/03/12/2-high-yield-dow-jones-dividend-stocks-to-buy-now/",
            "time_published": "20240312T105300",
            "authors": [
                "Cory Renauer"
            ],
            "summary": "These industry leaders boast advantages that could expand their bottom lines for decades.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F768701%2Finvesting-screen-analysis-investor-growth-stocks-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.268909,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "0.022017",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VZ",
                    "relevance_score": "0.236972",
                    "ticker_sentiment_score": "0.049603",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.236972",
                    "ticker_sentiment_score": "0.213688",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "J&J  ( JNJ )  Seeks Expanded Use of Tremfya for Ulcerative Colitis",
            "url": "https://www.zacks.com/stock/news/2239023/jj-jnj-seeks-expanded-use-of-tremfya-for-ulcerative-colitis",
            "time_published": "20240312T093900",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Tremfya is an important drug in J&J's (JNJ) immunology drugs portfolio and a key driver of top-line growth.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.233709,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.080728",
                    "ticker_sentiment_score": "0.140668",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RXDX",
                    "relevance_score": "0.080728",
                    "ticker_sentiment_score": "0.013242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.080728",
                    "ticker_sentiment_score": "0.140668",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.31482",
                    "ticker_sentiment_score": "0.12655",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.238913",
                    "ticker_sentiment_score": "0.142881",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson  ( JNJ )  Increases Despite Market Slip: Here's What You Need to Know",
            "url": "https://www.zacks.com/stock/news/2238883/johnson-johnson-jnj-increases-despite-market-slip-heres-what-you-need-to-know",
            "time_published": "20240311T214519",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The latest trading day saw Johnson & Johnson (JNJ) settling at $161.23, representing a +1.07% change from its previous close.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default83.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.961735"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.169927,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.590482",
                    "ticker_sentiment_score": "0.152388",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "U.S. 1st Latino Tech Payroll Startup Trez.co, Announces Advisory Board of Industry Giants and C-Suite Executives As It Opens Its Scaling Seed Round",
            "url": "https://www.prnewswire.com/news-releases/us-1st-latino-tech-payroll-startup-trezco-announces-advisory-board-of-industry-giants-and-c-suite-executives-as-it-opens-its-scaling-seed-round-302085701.html",
            "time_published": "20240311T200000",
            "authors": [
                "Trez Inc"
            ],
            "summary": "U.S. 1st Latino Tech Payroll Startup Trez.co, Announces Advisory Board of Industry Giants and C-Suite Executives As It ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/2359562/Advisory_Board_of_Industry.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.413784,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CSCO",
                    "relevance_score": "0.042421",
                    "ticker_sentiment_score": "0.100646",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WM",
                    "relevance_score": "0.042421",
                    "ticker_sentiment_score": "0.098471",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.042421",
                    "ticker_sentiment_score": "0.169062",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "K",
                    "relevance_score": "0.042421",
                    "ticker_sentiment_score": "0.169062",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ICNB",
                    "relevance_score": "0.042421",
                    "ticker_sentiment_score": "0.169062",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JACK",
                    "relevance_score": "0.042421",
                    "ticker_sentiment_score": "0.100646",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EC",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.315895",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Insights Into Johnson & Johnson's Performance Versus Peers In Pharmaceuticals Sector - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/insights/news/24/03/37592617/insights-into-johnson-amp-johnsons-performance-versus-peers-in-pharmaceuticals-sector",
            "time_published": "20240311T160051",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors and industry enthusiasts. In this article, we will perform an extensive industry comparison, evaluating Johnson & Johnson JNJ in relation to its major competitors in ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.961735"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.249941,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.065327",
                    "ticker_sentiment_score": "0.139242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.433877",
                    "ticker_sentiment_score": "0.346803",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "UM Named Ad Age A-List 2024 Media Agency of the Year - PR Newswire",
            "url": "https://www.prnewswire.com/news-releases/um-named-ad-age-a-list-2024-media-agency-of-the-year-302085369.html",
            "time_published": "20240311T140000",
            "authors": [],
            "summary": "UM Named Ad Age A-List 2024 Media Agency of the Year PR ...",
            "banner_image": null,
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.579266,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "SNEJF",
                    "relevance_score": "0.098659",
                    "ticker_sentiment_score": "0.197768",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MAT",
                    "relevance_score": "0.098659",
                    "ticker_sentiment_score": "0.197768",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SPOT",
                    "relevance_score": "0.098659",
                    "ticker_sentiment_score": "0.197768",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GPRO",
                    "relevance_score": "0.098659",
                    "ticker_sentiment_score": "0.197768",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.098659",
                    "ticker_sentiment_score": "0.197768",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.098659",
                    "ticker_sentiment_score": "0.197768",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AXP",
                    "relevance_score": "0.098659",
                    "ticker_sentiment_score": "0.197768",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ACN",
                    "relevance_score": "0.098659",
                    "ticker_sentiment_score": "0.197768",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Neptune Software: 'Environmental Supply Chains - You Don't Need to Sacrifice Profitability to Act Sustainably'",
            "url": "https://www.prnewswire.com/news-releases/neptune-software-environmental-supply-chains---you-dont-need-to-sacrifice-profitability-to-act-sustainably-302083164.html",
            "time_published": "20240311T111500",
            "authors": [
                "Neptune Software"
            ],
            "summary": "OSLO, Norway, March 11, 2024 /PRNewswire/ -- As the urgency to achieve net-zero carbon emissions by 2050 increases, it's more important than ever before that companies do their part to address growing environmental and climate concerns worldwide.",
            "banner_image": "https://mma.prnewswire.com/media/800029/Neptune_Software_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.305623,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.117774",
                    "ticker_sentiment_score": "0.033522",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March",
            "url": "https://www.fool.com/investing/2024/03/11/dividend-kings-healthcare-stocks-to-buy-in-march/",
            "time_published": "20240311T093500",
            "authors": [
                "Justin Pope"
            ],
            "summary": "These are some of the best-performing stocks in what's arguably society's most important industry.",
            "banner_image": "https://g.foolcdn.com/editorial/images/767296/jnj.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                }
            ],
            "overall_sentiment_score": 0.319223,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.051886",
                    "ticker_sentiment_score": "0.015964",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.103554",
                    "ticker_sentiment_score": "0.184254",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BDX",
                    "relevance_score": "0.20537",
                    "ticker_sentiment_score": "0.211033",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.255106",
                    "ticker_sentiment_score": "0.149871",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Major shareholder announcement - BlackRock, Inc.",
            "url": "https://www.globenewswire.com/news-release/2024/03/11/2843540/0/en/Major-shareholder-announcement-BlackRock-Inc.html",
            "time_published": "20240311T093000",
            "authors": [
                "Chemometec A/S"
            ],
            "summary": "ANNOUNCEMENT NO. ...",
            "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/dda6d08e-1d43-433e-bc7b-b1e84b4963be",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.164459,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.541149",
                    "ticker_sentiment_score": "0.344368",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.288893",
                    "ticker_sentiment_score": "0.08505",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.288893",
                    "ticker_sentiment_score": "0.08505",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.288893",
                    "ticker_sentiment_score": "0.08505",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Legal Challenges To IRA Drug Price Negotiations Face Skeptical Judges",
            "url": "https://www.forbes.com/sites/joshuacohen/2024/03/09/legal-challenges-to-ira-drug-price-negotiations-face-skeptical-judges/",
            "time_published": "20240309T174448",
            "authors": [
                "Joshua Cohen"
            ],
            "summary": "A district court judge in New Jersey heard oral arguments this week with respect to claims brought forth by four pharmaceutical companies that the Inflation Reduction Act's drug price negotiation provision violates certain constitutional rights.",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65eb1178e7f08fb8331f00d8/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.009656,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "FGROF",
                    "relevance_score": "0.028456",
                    "ticker_sentiment_score": "0.013937",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.169477",
                    "ticker_sentiment_score": "0.018762",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.056876",
                    "ticker_sentiment_score": "-0.035",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.028456",
                    "ticker_sentiment_score": "-0.016752",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.028456",
                    "ticker_sentiment_score": "-0.016752",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year",
            "url": "https://www.prnewswire.com/news-releases/new-data-shows-jnj-2113-the-first-and-only-investigational-targeted-oral-peptide-maintained-skin-clearance-in-moderate-to-severe-plaque-psoriasis-through-one-year-302084693.html",
            "time_published": "20240309T170000",
            "authors": [
                "Johnson & Johnson"
            ],
            "summary": "New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/2333578/Johnson_and_Johnson_Logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.090321,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "PTGX",
                    "relevance_score": "0.234946",
                    "ticker_sentiment_score": "0.160622",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.740019",
                    "ticker_sentiment_score": "0.17013",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology  ( AAD )  Annual Meeting",
            "url": "https://www.benzinga.com/pressreleases/24/03/g37574324/samsung-bioepis-presents-two-abstracts-for-its-immunology-portfolio-at-the-2024-american-academy-o",
            "time_published": "20240309T150500",
            "authors": [
                "Globe Newswire"
            ],
            "summary": "INCHEON, Korea, March 09, 2024 ( GLOBE NEWSWIRE ) -- Samsung Bioepis Co., Ltd. presented two new study results for its immunology portfolio - SB5, a biosimilar to Humira1 ( adalimumab ) , and SB17, a proposed biosimilar to Stelara2 ( ustekinumab ) - at the 2024 American Academy of Dermatology ( ...",
            "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.064972,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "SSNLF",
                    "relevance_score": "0.162802",
                    "ticker_sentiment_score": "0.119639",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.023418",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.023418",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OGN",
                    "relevance_score": "0.023418",
                    "ticker_sentiment_score": "0.066965",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Johnson & Johnson Unusual Options Activity For March 08 - Johnson & Johnson  ( NYSE:JNJ ) ",
            "url": "https://www.benzinga.com/insights/options/24/03/37566466/johnson-johnson-unusual-options-activity-for-march-08",
            "time_published": "20240308T190104",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Deep-pocketed investors have adopted a bearish approach towards Johnson & Johnson JNJ, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.171533,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.075635",
                    "ticker_sentiment_score": "0.140603",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.552443",
                    "ticker_sentiment_score": "0.299646",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Retail Investors Could Make $2,000 on Cummins Exchange Offer. Here's How.",
            "url": "https://www.barrons.com/amp/articles/cummins-exchange-offer-atmus-98ddf4d2",
            "time_published": "20240308T184100",
            "authors": [
                "Andrew Bary"
            ],
            "summary": "An exchange offer by Cummins , the diesel engine maker, for shares in Atmus Filtration Technologies allows small investors to fully participate and potentially make about $2,000 on the trade in the next week or so.",
            "banner_image": "https://images.barrons.com/im-09529025/social",
            "source": "Barrons",
            "category_within_source": "n/a",
            "source_domain": "www.barrons.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.692272"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.237375,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.081552",
                    "ticker_sentiment_score": "0.085584",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ATMU",
                    "relevance_score": "0.081552",
                    "ticker_sentiment_score": "0.063122",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.081552",
                    "ticker_sentiment_score": "0.085584",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        }
    ]
}